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This dissertation illustrates the role of nitric oxide (NO) in regulating coronary tone and 
how impairment of NO bioavailability not only influences coronary vasoregulation but also the 
roles of other vasoactive mediators, namely the endothelial-derived hyperpolarizing factor 
(EDHF), hydrogen sulfide (H2S).   
To investigate coronary function in a physiological setting, a novel technique using high-
resolution ultrasound was developed to measure coronary vasodilatory response in vivo.  With 
this method, coronary vasodilatory function was evaluated in terms of increase in coronary blood 
flow velocity.  Vasorelaxation was induced by intravenous infusion of adenosine triphosphate 
and by increasing myocardial demand with β-adrenergic receptor agonist dobutamine. This 
approach was further adapted to measure ascending aortic stiffness in vivo, a systemic parameter 
that influences coronary function.  Aortic diameter was measured by ultrasound while aortic 
pressure was measured invasively by pressure catheter. Vasoactive drugs were infused to 
modulate aortic pressure to obtain a pressure-diameter relationship of the ascending aorta. 
These ultrasound-based techniques were then applied to investigating the effects of 
ionizing radiation exposure on coronary artery function. Rats exposed to ionizing radiation 
exhibited reduced coronary flow in vivo.  Decreased coronary flow was associated with both 
decreased aortic diastolic pressure and elevated superoxide content in the coronary artery.  
Reduced diastolic pressure was attributed to decreased heart rate. Reduction of superoxide 
production by xanthine oxidase inhibition partially restored basal coronary flow and coronary 
superoxide content.  However, in vivo vasodilatory response was not improved. Moreover, 
endothelial function was preserved in irradiated rats. These findings support that radiation-
associated coronary artery disease is initiated by an increase in superoxide level, which leads to 
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reduced NO bioavailability and diminished coronary vasodilatory response in vivo.  The data 
further suggest that excess superoxide production precedes coronary endothelial dysfunction 
characteristic of coronary artery disease. 
Next, the role of endogenously produced H2S in coronary tone vasoregulation and the 
interaction between NO and H2S were examined. Both cystathionine gamma lyase (CSE) and 3-
mercaptopyruvate sulfurtransferase (MPST), the enzymatic producers of H2S in the vasculature, 
were detected in human coronary endothelial cells and rat coronary arteries. In vitro 
measurement of H2S production showed that the rat coronary artery can produce H2S through the 
MPST pathway but not through the CSE pathway.  Both pharmacologic inhibition and genetic 
deletion of CSE did not alter coronary vasodilatory function in vivo, supporting that CSE-
produced H2S does not have a significant role in coronary vasoregulation. Ex vivo coronary 
vasoreactivity response to MPST substrate 3-mercaptopyruvate (3-MP) was similar to the 
vasoreactivity response to H2S donor sodium hydrosulfide (NaHS), supporting that vasoactive 
effects of 3-MP were through MPST-mediated production of H2S.  The data demonstrate that 
H2S production in the coronary artery is mediated by MPST and not CSE, contrary to other 
vascular beds where CSE has a significant role.  The data further show that the vasoactive effect 
of H2S is NO dependent: H2S induces coronary vasoconstriction in the presence of NO and 
vasorelaxation in the absence of NO. Vasoconstrictive effects of H2S appear to be due to its 
scavenging of NO and the resulting decrease in NO bioavailability. 
This dissertation illustrates how altering the bioavailability of NO not only influences 
coronary vasodilatory function but also the roles of other vasoactive mediators in coronary 
vasoregulation.  This dissertation further demonstrates the significance of in vivo influences on 
vascular function and the power of implementing a multi-level approach in studying vascular 
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function.  Changes in cellular signaling can be correlated to changes in physiological function, 
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Because oxygen extraction in the myocardium is maximal, increased metabolic demand 
of the myocardium can only be matched by increasing coronary blood flow.  Blood flow can 
only be increased by vasodilation of the coronary artery.  Impaired vasodilatory response of the 
coronary vasculature therefore results in insufficient supply of blood and oxygen, leading to 
myocardial ischemia, as documented in patients with coronary artery disease. Identifying and 
characterizing mechanisms underlying coronary tone regulation is therefore of clinical relevance. 
 A sequence of events occurs to result in vasorelaxation of the coronary artery (Fig. P.1).  
The cascade is initiated by an external stimulus, such as neurohumoral release of acetylcholine, 
myocardial release of adenosine, and red blood cell release of adenosine triphosphate (ATP).  
These factors bind to their corresponding receptors on the endothelium and stimulate the 
endothelium to produce vasodilators.  The three vasodilating mediators produced are nitric oxide 
(NO), prostanoids, and endothelium-derived hyperpolarizing factors (EDHFs).  NO is produced 
predominantly by endothelial nitric oxide synthase (eNOS) from L-arginine. Prostanoids are 
produced from arachidonic acid mainly by cyclooxygenase.  Prostanoids can be dilating or 
constricting: the overall vasoactive effect depends on which influence is more dominant.  EDHFs 
are produced from a variety of sources, including cystathionine gamma lyase (CSE) and 3-
mercaptopyruvate sulfurtransferase (MPST).  Each type of vasoactive mediator has been 
demonstrated to be involved in coronary vasorelaxation, including maintaining baseline tone and 
mediating metabolic demand-induced or flow-induced vasodilation.  Coronary vasorelaxation is 
therefore a concerted effect.  The vasoactive mediators then stimulate pathways in the vascular 
smooth muscle cell that ultimately result in the opening of potassium (K
+
) channels, causing 
hyperpolarization and vasorelaxation of the smooth muscle cells.  NO acts through guanylyl 
2 
 
cyclase and cyclic guanosine monophosphate (cGMP) while the vasodilating prostanoids act 




 Impaired vasodilatory response theoretically can arise at each stage: decreased external 
stimuli release, impaired endothelial production or decreased bioavailability of vasodilating 
mediators, or dysregulated downstream signaling in the vascular smooth muscle cells. 
Cardiovascular disease has been established to result from impaired endothelial function, leading 
to diminished production and bioavailability of vasodilators, notably NO, in the vasculature.  
This dissertation focuses on the role of NO in coronary tone regulation and examines how 
impairment of NO influences coronary vasodilatory function and the roles of other vasoactive 
mediators, specifically a novel EDHF hydrogen sulfide (H2S).  Chapter 1 describes two novel 
approaches for measuring vascular function in vivo in mouse and rat models using ultrasound 
imaging. Section 1.1 describes a technique for measuring coronary vasodilatory function and 
Section 1.2 describes a technique for measuring ascending aortic stiffness, a systemic parameter 
that influences coronary function. Chapter 2 investigates the effects of ionizing radiation 
exposure on coronary artery function and NO bioavailability. Chapter 3 examines the role of 
endogenously produced H2S in coronary tone vasoregulation and the interaction between H2S 

































CHAPTER 1: MEASURING VASCULAR FUNCTION IN VIVO USING ULTRASOUND 
IN MOUSE AND RAT MODELS 
 
1.1 MEASURING CORONARY VASODILATORY FUNCTION IN VIVO 
1.1.1. INTRODUCTION 
Vascular function is generally evaluated by the vessel’s relaxation response to 
vasodilating drugs.  The standard approach to characterizing vasorelaxation behavior 
experimentally is by myography in which the vessel is excised from the animal and experiments 
are performed directly on the vessel.  Two types of myography set-ups exist: wire myography 
that records the tension produced by vessel when it constricts using a force transducer, and 
pressure myography that tracks the diameter of the vessel optically with a video camera.  The 
experimental procedure is the same for either set-up. The vessel is first pre-constricted with a 
vasoconstricting agent, for instance phenylephrine or prostaglandin F2α. Increasing doses of a 
vasodilator are then added to relax the vessel to obtain a dose-dependent vasorelaxation 
response.  On the wire myograph, vessel constriction produces an increase in measured tension 
and as the vessel relaxes, tension decreases.  On the pressure myograph, vasoconstriction results 
in a decrease in vessel diameter and diameter increases as the vessel relaxes. Cellular function 
can be evaluated by using drugs that induce vasodilation through specific pathways. 
Acetylcholine (Ach) is commonly used to stimulate the endothelium to induce vasorelaxation.  
Sodium nitroprusside (SNP), a donor of NO, is used to stimulate the smooth muscle cells.   
Endothelial function can be assessed by comparing the endothelial-mediated 
vasorelaxation response with the endothelial-independent response.  Impaired endothelial-
dependent relaxation, either in terms of decreased sensitivity to Ach or diminished maximal Ach-
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induced vasodilation or both, in the presence of intact endothelial-independent relaxation support 
altered endothelial function.  Impaired endothelial-dependent relaxation combined with impaired 
endothelial-independent relaxation, however, would be inconclusive as it would not be clear if 
endothelial function was impaired or if smooth muscle function was impaired. 
Clinically, coronary artery health is measured in patients by administering a coronary 
vasodilator, such as adenosine or adenosine triphosphate (ATP) [1], to induce maximal coronary 
vasodilation.  Vasodilation is measured as the increase in coronary flow velocity.  Coronary flow 
velocity during maximal vasodilation, hyperemia, is normalized to coronary flow at baseline.  
This ratio is called coronary flow velocity reserve (CFVR). Coronary vasodilation also is 
induced by increasing myocardial oxygen demand through exercise or by pharmacologic 
intervention, such as with β-adrenergic agonist dobutamine.  Patients with coronary artery 
disease display decreased maximal vasodilation, which manifests as decreased hyperemic flow 
velocity, resulting in a lower CFVR value.   
Although measuring coronary vasorelaxation ex vivo allows for more precise mechanistic 
investigations, evaluating vasorelaxation response in vivo provides a physiologically 
representative indication of coronary function.  This section describes a novel technique for 
measuring coronary vasodilatory function in mouse and rat models by combining the ex vivo 
approach for measuring vasorelaxation response with the technique used clinically to assess 
coronary function in patients.  Coronary vasorelaxation is measured through increase in flow 
velocity using ultrasound.  Vasorelaxation is induced by intravenous infusion of ATP and by 
increasing myocardial demand with dobutamine. Because vasodilatory function can be altered in 
terms of both sensitivity to the vasodilator and the degree of maximal vasodilation, obtaining a 
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vasorelaxation response offers more conclusive data compared to measuring only maximal 
vasorelaxation.   
 
1.1.2. METHODS 
1.1.2.1. Transthoracic echocardiography 
Coronary flow velocity is measured in vivo using transthoracic echocardiography as 
previously described [2]. The animal is anesthetized with 1.5% isoflurane. Chest hair is removed 
by depilatory cream.  The animal is secured onto a heated platform to monitor ECG, heart rate, 
and body temperature.  Coronary flow velocity is measured using the Vevo 2100 (Visual Sonics) 
and a 40 MHz transducer (Visual Sonics).  The ultrasound station set-up is shown in Fig. 1.1.1.   
The transducer is positioned laterally on the left side of the animal to obtain an image of 
the left ventricle, left atrium, and aorta.  From this view, the left coronary artery is visualized by 
color flow Doppler (Fig. 1.1.2).  Flow velocity profile of the blood flow through the coronary 
artery is captured by pulse wave velocity.  The transducer is mounted on a stand (Visual Sonics) 
to measure flow velocity from the same location for the entire experiment.  The difference in 
angle between blood flow and ultrasound beam is accounted for with angle correction done on 
the Vevo mainframe. 
 
1.1.2.2. Coronary vasoreactivity 
Catheters are custom-made by attaching a 30-gauge needle (BD) to size PE-10 
polyethylene tubing (BD).  The animal is warmed for ~5 minutes to dilate the peripheral veins.  
A tourniquet is tied at the base of the tail to visualize the lateral tail vein.  The needle is inserted 
into the tail vein and the catheter is connected to a syringe placed in a syringe pump (Harvard 
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Apparatus).  Vasodilating drugs are administered intravenously through the catheter.  Increase in 
coronary artery diameter corresponds with an increase in flow velocity.  Dose of drug 
administered is controlled with a syringe pump by adjusting infusion rate (Harvard Apparatus).   
Coronary vasorelaxation is induced by intravenous infusion of adenosine triphosphate 
(ATP, Sigma) or β-adrenergic agonist dobutamine (Dob, Hospira). ATP is administered to 
evaluate agonist-induced coronary vasorelaxation and dobutamine to evaluate metabolic 
demand-mediated vasorelaxation.  Working concentration of ATP is 0.5 mg/mL. ATP is infused 
at 20, 40, 80, and 160 µg/kg/min for 1 minute per dose.  Coronary flow velocity is allowed to 
return to baseline between each dose.  The working concentration of dobutamine is 0.2 mg/mL.  
Dobutamine is infused at 5, 10, 20, and 30 µg/kg/min at 2 minutes per dose.  All drugs are 
prepared in a heparinized 0.9% saline solution.  Peak diastolic flow velocities of three cardiac 
cycles are measured for data analysis. 
 
1.1.3. RESULTS 
Modified long axis view obtained to visualize the left main coronary artery is shown in 
Figure 1.1.2.  Increasing dose of ATP causes a dose-dependent increase in coronary flow 
velocity, as shown in Figure 1.1.3.  Flow velocity at baseline is shown in (1.1.3A), at 40 
µg/kg/min is shown in (1.1.3B), and at 160 µg/kg/min is shown in (1.1.3C).  Peak flow velocity 
can be plotted against dose of ATP, as shown in Figure 1.1.4A, and dose of dobutamine, as 
shown in Figure 1.1.4B, to show agonist-dependent and myocardial demand-dependent increase 





This technique is a physiologically-relevant functional assessment of coronary health.  
Moreover, because drugs are infused through a catheter inserted into the tail vein, the procedure 
is non-invasive and allows for multiple time-point measurements in the same animal.  When 
combined with ex vivo and in vitro assessment of coronary function, a complete evaluation of 
coronary health can be obtained. 
 One disadvantage of this method is that cellular function cannot readily be evaluated as 
with ex vivo myography techniques.  ATP causes endothelial-dependent coronary vasodilation ex 
vivo [3].  In vivo, however, ATP is hydrolyzed by ectonucleotidases to adenosine, adenosine 
monophosphate (AMP), and adenosine diphosphate (ADP) [4].  Vasodilation that occurs in vivo 
with ATP administration results from the combined effect of adenosine, AMP, ADP, and ATP.  
ATP and ADP act through the P2Y purinergic receptors while adenosine and AMP act through 
the P1 purinergic receptors [5].  These receptors are expressed in both endothelial and vascular 
smooth muscle cells, so vasodilation occurs through both endothelial-dependent and –
independent pathways [6]. 
 Ach could be administered to examine endothelial function.  However, during our 
studies, we observed that systemic administration of Ach resulted in decreased flow velocity, 
indicating coronary vasoconstriction.  Moreover, flow velocity changes are in the range of 100 
mm/s, which is within the margin of uncertainty of the ultrasound measurements.  Nevertheless, 
ATP and dobutamine-induced increase in myocardial demand are physiologically-relevant 
stimuli so coronary function measured through the administration of these drugs provides an 








Figure 1.1.1. Ultrasound station set-up.  The Vevo 2100 is used to for ultrasound experiments. 
The mainframe is in the foreground.  The probe is mounted on the rail system so that 
measurements can be made from the same location for the duration of the experiment.  A 
catheter is inserted into the tail vein for intravenous administration of vasodilating drugs.  Dose 




Figure 1.1.2. Locating the left descending coronary artery. Ultrasound probe is placed on the left 
side of the animal to obtain a long axis view of the aorta (Ao) and left ventricle (LV).  The left 
coronary artery (LCA) is visualized by color Doppler and can be identified as coming off of the 








Figure 1.1.3. Coronary blood flow velocity profile. Blood flow velocity profile is captured by 
pulse wave velocity.  Both systolic and diastolic portions are visible. (A) shows a representative 
flow velocity profile at baseline.  Increasing dose of vasodilator increases both systolic and 
diastolic flow velocities, although the increase in diastolic flow velocity is more dramatic. (B) 
shows the flow velocity profile at 40 µg/kg/min ATP and (C) shows the flow velocity profile at 








Figure 1.1.4.  Dose-dependent increase in peak diastolic flow velocity.  Peak diastolic flow 
velocity is measured for data analysis.  Increasing ATP dose causes a dose-dependent increase in 
flow velocity (A).  Increasing dobutamine (Dob) dose similarly causes a dose-dependent increase 


















Increased aortic stiffness is a hallmark of cardiovascular disease. Aging [7], smoking [8], 
diabetes [9], hyperlipidemia [10], and other risk factors of cardiovascular disease have been 
shown to increase aortic stiffness. Epidemiological studies have further demonstrated aortic 
stiffness as a powerful independent predictor of the onset of coronary heart disease and stroke, as 
well as the occurrence of cardiovascular events and mortality [11-14]. Because of the clinical 
and public health significance of increased aortic stiffness, current research is focused on 
understanding the mechanisms underlying the development and progression of vascular stiffness. 
Great interest therefore exists in developing accurate measures of vascular stiffness in 
experimental models of cardiovascular disease.  
A material’s stiffness can be characterized by its stress-strain relationship and quantified 
as elastic modulus. A linear elastic material deforms reversibly and its stress increases 
proportionally to strain. The aorta and the large arteries are nonlinear elastic bodies: when 
stretched, the stiffness of the artery does not remain constant but increases with the degree of 
distension. This nonlinearity in the mechanical properties of large arteries is due to the different 
stiffness properties of the load-bearing elements, namely elastin and collagen, that constitute the 
vessel wall. Elastin is highly extensible with an elastic modulus of 0.6 MPa. In comparison, 
collagen is very stiff with an elastic modulus of 1 GPa [15]. The initial stiffness exhibited by the 
aorta at lower strain values is attributed to elastin while the high stiffness exhibited at high strain 
values is due to collagen. Load is transferred from elastin to collagen as the vessel distends and 
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this region of load transferring is where the vascular system operates. Therefore, at physiologic 
pressures, arterial stiffness depends on the contribution of both elastin and collagen [16]. 
The distribution and orientation of elastin and collagen vary by layer within the arterial 
wall. In the media, the elastin, collagen, and smooth muscle cells are bundled into tight helices 
that are layered concentrically. This arrangement allows the artery to resist high loads in the 
circumferential direction. The adventitia is predominantly collagen with little elastin and the 
collagen fibers are organized in a net-like fashion. These collagen fibers are wavy in an 
unstressed state and straighten out as load increases. Stiffness increases as the collagen fibers 
straighten out, thereby preventing the artery from overstretching and rupturing. Because of the 
structural organization and varying orientation of the collagen fibers, arteries are anisotropic: the 
stiffness exhibited depends on if the vessel is stretched longitudinally or circumferentially [17]. 
In vivo stiffness is therefore a composite of the aorta’s longitudinal and circumferential stiffness. 
Arterial stiffness is generally quantified in vivo as compliance or pulse wave velocity 
(PWV). Arterial compliance is defined as C = ∆D / ∆P where ∆D is change in diameter and ∆P is 
the corresponding change in pressure. Lower values of compliance indicate stiffer vessels. 
Compliance is calculated from the pressure-dimension relationship of the artery and is therefore 
a direct measure of stiffness. As stiffness is disseminated non-uniformly in the vasculature [18], 
compliance should be measured at the same/similar location in each subject to make meaningful 
comparisons between experimental groups. 
The difference between compliance and elastic modulus is that elastic modulus is 
normalized to the material’s dimensions. Compliance therefore reflects structural stiffness 
whereas elastic modulus reflects material stiffness. With aging, arterial wall thickness increases 
and elastin/collagen ratio decreases, so both structural stiffness and material stiffness are greater. 
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Compared to compliance, PWV is an indirect measure of arterial stiffness. PWV is the 
speed at which a pressure pulse travels along a length of artery and is influenced by the 
properties of the vessel wall. The Moens-Korteweg equation is used to model the relationship 
between PWV and elastic modulus: PWV
2
 = E h / (2 ρ r) where E is incremental elastic modulus, 
h is wall thickness, ρ is blood viscosity, and r is vessel radius. A higher PWV value therefore 
suggests a stiffer vessel. 
 Compliance and elastic modulus can be measured experimentally ex vivo on an excised 
segment of vessel. To determine compliance, the vessel segment is mounted on a pressure 
myograph [19,20]. Pressure within the vessel is increased step-wise and the resulting change in 
diameter is tracked using video microscopy. Compliance is determined from the pressure-
diameter data. Incremental elastic modulus can be measured by tensile testing. In these 
experiments, the vessel is pulled apart step-wise and force-displacement data is collected until 
the vessel ring breaks. Stress and strain values can be calculated and plotted to determine 
incremental elastic modulus. These ex vivo approaches can be used to evaluate changes in the 
passive properties that influence stiffness.  
In vivo, in addition to wall content, vascular stiffness is influenced dynamically by 
smooth muscle tone and blood pressure [19,21,22]. PWV is the most widely used method for 
measuring in vivo aortic stiffness in experimental models. PWV can be determined non-
invasively using Doppler ultrasound or applanation tonometry [23]. Pressure pulse is measured 
at two separate locations and the time required for the pulse to traverse the distance is the pulse 
wave velocity. Because PWV is measured over a length of aorta, it is an averaged value of 
stiffness. Large arteries are nonlinear elastic, so stiffness and therefore PWV will vary with 
arterial pressure. A higher PWV value could therefore arise from increased stiffness or elevated 
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pressure. PWV values therefore must be normalized to blood pressure to derive conclusions 
about the vessel’s stiffness. Measurement methods that incorporate the influence of blood 
pressure with the passive properties of the vascular wall and the effects of vasoactive mediators 
that alter tone would yield a physiologically relevant index of arterial stiffness. This approach is 
implemented by measuring PWV invasively using a catheter with two pressure sensors separated 
at a fixed distance [19]. This dual-pressure catheter is inserted into the aorta and vasoactive 
drugs such as phenylephrine or sodium nitroprusside are infused intravenously through a venous 
catheter to raise and lower arterial pressure. 
This protocol describes a method to determine aortic stiffness in vivo from its pressure-
dimension relationship in a mouse model. This approach offers several advantages over the 
invasive PWV measurement. Stiffness indices, such as compliance, can be calculated from the 
pressure-dimension data collected by this procedure. Moreover, this technique allows for 
measurement of local aortic stiffness because stiffness is measured from a single location. This 
approach is particularly useful in measuring ascending aortic stiffness as the short length of this 
region makes a PWV measurement difficult to obtain. Research interest exists specifically in the 
ascending aorta because its mechanical properties influence the perfusion of the coronary 
circulation and the cardiac response to vascular dysfunction.  
To measure the pressure-diameter relationship of the aorta in vivo, the ascending aorta is 
visualized and its diameter is measured by ultrasound imaging. Aortic blood pressure is 
measured invasively with a pressure catheter. Blood pressure is changed incrementally by 
intravenous infusion of vasoactive drugs. Phenylephrine constricts blood vessels and is used to 
raise aortic pressure. Sodium nitroprusside dilates blood vessels and is used to lower aortic 
pressure. Systolic and diastolic aortic diameters and corresponding aortic pressures are measured 
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This protocol has been approved by the Institutional Animal Care and Use Committee at Johns 
Hopkins University. 
 
1. Preparation of solutions, materials, and animal 
1.1) Prepare a 300 µg/ml solution of phenylephrine (PE) and 300 µg/ml solution of sodium 
nitroprusside (SNP) in 0.9% saline. Prepare a separate heparin-saline solution by mixing 1 mL of 
1000 U/mL heparin into 10 mL 0.9% saline. Note: Drugs should be at room temperature before 
use.  
1.2) Make the catheter for intravenous drug infusion from two 30G x ½” hypodermic needles 
and PE 10 polyethylene tubing. To make the catheter, insert one needle into one end of the 
tubing. Remove the needle portion of the other hypodermic needle and insert the blunt end into 
the other end of the tubing. Attach the catheter to a 1 ml syringe and fill the catheter with the 
heparin-saline solution.  
1.3) Place mouse in the anesthesia induction chamber containing 2-2.5% isoflurane in 100% 
oxygen. Leave the mouse in the induction chamber until it is unresponsive to external stimuli. 
Remove the mouse from the induction chamber and place it on the heated electrocardiogram 
(ECG) pad. Maintain the animal at 2% isoflurane. 
1.4) If necessary, apply vet ointment or saline solution to the animal’s eyes to prevent dryness 




2. Insertion of catheter into tail vein 
2.1) Since the tail veins are located laterally on both sides of the tail, place the animal on its side 
for better access. Secure the mouse onto the ECG pad with tape. Make sure the animal is kept 
warm to promote vasodilation of the tail veins. 
2.2) Using a piece of silastic tubing as a tourniquet, tie the tourniquet around the base of the tail. 
Tie the tourniquet tight enough to collapse the veins but not enough to cut off the arterial 
circulation. After 2-3 minutes, the vein should bulge out and become more visible. 
2.3) Gently pull the tail taut. Bend the tail at an angle with one hand and hold the needle parallel 
to the tail with the other. Pierce the needle where the tail is bent through the skin into the vein. 
Blood will push back into the catheter if the needle is inserted into the vein. 
2.4) Place one drop of tissue glue where the needle is inserted to secure the catheter. Remove the 
tourniquet and confirm patency by injecting saline with little resistance. 
 
3. Insertion of blood pressure catheter through femoral artery  
3.1) Place the pressure catheter into a 30 ml syringe filled with distilled water and connect the 
catheter to the pressure control unit. The catheter should soak in water, plugged in, for 30-45 
minutes during the set-up and surgery procedures. 
3.2) Place the animal supine and tape its paws onto the ECG pad. Apply depilatory cream on the 
chest and area over the femoral artery.  
3.2.1) Wait 3-5 minutes and remove cream and hair. Hair must be thoroughly removed from the 
chest to prevent artifacts during the ultrasound. Wipe both the chest and hind limb regions with a 
moistened pad to remove excess depilatory cream. 
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3.3) Using fine scissors, make an incision in the skin above the location of the femoral artery. 
Dissect through the subcutaneous fat tissue to reveal the femoral artery. The femoral artery is 
partially covered by the abdomen. Use hemostats to move the abdomen away.  
3.4) Using fine forceps, separate the nerve away from the artery-vein bundle. Gently pierce 
through the sheath around the artery-vein bundle to separate the artery from the vein. Pass one 
suture around the artery at the proximal end and place two sutures at the distal end.  
3.5) Securely knot the most distal suture to stop distal blood flow. Use hemostats to pull the 
proximal suture to temporarily stop blood flow into the femoral artery. Use microscissors to 
make a small incision into the femoral artery. Make the incision near the distal knot. 
3.6) Calibrate the data acquisition software to the catheter using the calibration settings on the 
pressure control unit. Switch the pressure control unit back to reading the transducer and balance 
the pressure catheter so that the catheter outputs 0 mmHg in the water-filled syringe. 
3.7) Insert the catheter into the femoral artery. Open the incision with fine forceps with one hand 
and insert the catheter head into the artery with the other hand. Knot the middle suture around the 
catheter wire to secure the catheter into the artery. Relax the proximal suture and advance the 
catheter forward into the abdominal aorta. Knot the proximal suture to further secure the catheter 
and to prevent bleeding. 
3.8) Carefully move the ECG pad with mouse, pressure catheter and saline syringe to the 
ultrasound imaging stage. Connect the blood pressure catheter to the pressure control unit. Place 
the saline syringe in the syringe pump. Allow the animal to equilibrate for 20 minutes. This 





4. Measuring aortic diameter over a range of blood pressures 
4.1) Reduce isoflurane to 1.5%. Visualize the ascending aorta longitudinally on B-mode using a 
long axis view. Mount the transducer onto the rail system so that the same view is maintained for 
the duration of the experiment. 
4.2) On the ultrasound mainframe, place the M-mode cursor over the section of aorta to be 
tracked. Track the aortic diameter change over the cardiac cycle using M-mode. 
4.3) Change the saline in the syringe to the PE solution and place the syringe into the syringe 
pump.  
4.3.1) Record M-mode at baseline aortic pressure. Begin infusion at 360 µg/kg/min and infuse 
for 1 minute for aortic pressure to reach a plateau. For a 25 g mouse, this dose equates to 30 
µl/min. 
4.3.2) Record the M-mode, then stop the infusion, and wait 2 minutes for blood pressure to 
return to baseline. 
4.4) Lower infusion rate to 240 µg/kg/min. For a 25 g mouse, this dose equates to 20 µl/min. 
Start infusion, infuse for 1 minute for blood pressure to plateau, and record M-mode. Stop the 
infusion, and wait 2 minutes for blood pressure to return to baseline. 
4.5) Repeat step 4.4 for 120 µg/kg/min PE (10 µl/min for a 25 g mouse). 
4.6) Replace PE with saline and infuse the saline at the rate used for the 360 µg/kg/min infusion 
(30 µl/min for a 25 g mouse). Infuse for 2-3 minutes, until further infusion does not produce an 
increase in aortic pressure and pressure is returning to baseline. Wait 5 minutes for the blood 
pressure to stabilize at baseline. 
4.7) Replace saline with SNP.  
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4.7.1) Record M-mode at baseline aortic pressure. Begin infusion at 240 µg/kg/min (20 µl/min 
for 25 g mouse)and infuse for 1 minute. When aortic pressure reaches a plateau, record the M-
mode. Stop the infusion and wait 2 minutes for blood pressure to return to baseline.  
4.8) Lower infusion rate to 120 µg/kg/min (10 µl/min for 25 g mouse). Start infusion, infuse for 
1 minute for blood pressure to plateau, and record M-mode. Stop infusion and wait 2 minutes for 
blood pressure to return to baseline. 
4.9) Repeat step 4.8 for 60 µg/kg/min SNP (5 µl/minfor 25 g mouse). 
 
5. Terminating the experiment 
5.1) To euthanize the animal, increase isoflurane to 4%. When breathing has slowed, usually in 
1-2 minutes, cut through the sternum with scissors to open the thoracic cavity and expose the 
heart. 
5.2) Grasp the heart with medium forceps and excise it from the body by cutting at the ascending 
aorta with scissors.  
 
1.2.3. RESULTS  
A longitudinal image of the left ventricle and ascending aorta is captured on B-mode, as 
shown in Figure 1.2.1. Alternatively, a longitudinal image of only the aorta can be obtained, as in 
Figure 1.2.2. The movement of the aortic wall during the cardiac cycle appears as two white 
lines on the M-mode, as shown in Figure 1.2.3. The aortic lumen is the area in between the lines. 
Aortic pressure is modulated by infusion of vasoactive drugs. PE raises the aortic pressure, as 
shown in Figure 1.2.4A, and SNP lowers pressure, as shown in Figure 1.2.4B. M-mode is 
recorded when blood pressure plateaus, 1 minute after the start of infusion. Aortic pressure is 
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changed incrementally through changing the dose of the drug administered, as shown in Figure 
1.2.5. Dose of drug is controlled through the rate of infusion. All drug doses are in µg/kg/min. 
Maximum and minimum diameters are measured from the M-mode, shown in Figure 1.2.3. 
These diameters correspond to the systolic and diastolic aortic pressures recorded by the pressure 
catheter. 
Systolic and diastolic diameter and pressure values of three cardiac cycles are measured 
at baseline and for each PE and SNP dose. The standard deviation between three diameter 
measurements at one drug dose ranges from 0.01 mm to 0.04 mm. Aortic diameter can be plotted 
against its corresponding aortic pressure to illustrate the pressure-diameter relationship, as shown 
in Figure 1.2.6A. 
These pressure-diameter values are used to calculate aortic compliance. Arterial 
compliance is calculated by       C = (Dsys – Ddia) / (Psys – Pdia)  (1) 
where Dsys and Ddia are systolic and diastolic diameters and Psys and Pdia are systolic and 
diastolic pressures. Compliance and mean aortic pressure (MAP) are calculated at baseline and 
for each PE and SNP dose. Compliance is plotted against MAP to demonstrate the pressure-
dependency of stiffness. Because of the nonlinear elastic behavior of the aorta, compliance 
decreases with increasing MAP, as seen in Figure 1.2.6B.  
 
1.2.4. DISCUSSION  
Taking diameter measurements at several pressure increments over a wide range of 
pressure values is necessary for accurate characterization of the pressure-diameter relationship. 
The upper and lower pressure limits that can be pharmacologically induced may vary by the 
experimental group but the ideal range is around 25 mmHg to 125 mmHg diastolic and 50 
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mmHg to 200 mmHg systolic. Dose of 360 µg/kg/min PE and 240 µg/kg/min SNP generally 
elicit the limits of the pressure range. However, dose of PE can be increased to 480 µg/kg/min 
and SNP to 360 µg/kg/min to verify that the limits have been reached. Working concentrations 
of PE and SNP can be decreased to achieve finer pressure increments. As diameter will change 
with aortic pressure, inducing the same pressure values between animals and experimental 
groups is not important. 
Venous and arterial cannulation can be performed at other locations with the same 
outcomes. Tail vein cannulation can be challenging because of the small size of the tail vein. 
Moreover, the tail vein is not readily visible in dark-colored mice. The femoral vein can be 
cannulated as an alternative. This route may be easier since the femoral vein is more accessible. 
For pressure catheter insertion, besides the femoral artery, the catheter can be inserted through 
the carotid. The femoral artery is preferable over the carotid artery, however, because the chest 
region remains intact for the ultrasound imaging. Femoral artery cannulation can be more 
difficult because the femoral artery is smaller. Using a 1.2F catheter and introducing the catheter 
in the proximal femoral artery beneath the abdominal cavity will facilitate the cannulation 
process. Placing a few drops of a vasodilating agent like lidocaine onto the femoral artery or 
using a catheter introducer can also help enlarge the vessel to facilitate catheter insertion. The 
pressure catheter should be handled and used according to the manufacturer’s instructions. 
Location of the catheter within the aorta does not need to be consistent between animals 
as the pressure drop within the aorta is insignificant. However, placing the catheter in the 
abdominal aorta may be better to minimize interference with the ultrasound imaging of the 
thoracic aorta. Some ultrasound mainframes can record pressure real-time with the M-mode 
trace, thereby giving a pressure measurement for every diameter measured on the M-mode. 
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Unfortunately, because the location where the diameter is measured is not the same location as 
where pressure is recorded, a lag exists between the pressure recorded at the catheter and the 
actual pressure in the ascending aorta. As a result, only maximum and minimum diameter 
measurements can be used for the data analysis. 
The primary limitation of this method is the uncertainty in measurement introduced by 
the aorta shifting in and out of the ultrasound plane during the cardiac cycle. Motion-introduced 
error is common to all imaging-based studies, including MRI and CT. Compensation strategies 
include using anatomical features to shift the frame of reference with the movement [24] and are 
implemented during data processing. As motion compensation software is not readily available, 
the investigator has to be vigilant about adjusting the location of the probe to track the shift in 
location of the aorta as blood pressure rises and decreases. Diameter measurements should also 
be taken through the center of the aorta. However, determining whether the M-mode recording 
location is passing through the center can be difficult to judge on the ultrasound image, 
especially with the aorta shifting positions. The uncertainty introduced by these limitations 
manifest in the degree of scatter in the data, as evident in Figure 1.2.6. Obtaining an image of the 
cross-section instead of longitudinal axis of the ascending aorta could be a solution. However, 
obtaining this view can sometimes be more challenging and the resulting M-mode trace can be 
less clear. The cross-sectional circumference from the B-mode image could be measured instead 
of the diameter from the M-mode image. However, determining when maximum and minimum 
circumference has been achieved will be limited by the B-mode frame rate and may be more 
difficult to judge than on the M-mode. 
Making multiple measurements of the pressure-diameter plot and increasing experimental 
group size can improve accuracy of the data. The pressure-diameter data can be collected from 
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several locations along the chest. This protocol would first be carried out with the probe placed 
on one location on the chest. The aorta would then be visualized with the probe placed on 
another location and the protocol repeated.  
Vasoactive agents used to modulate blood pressure could potentially affect aortic smooth 
muscle tone, which in turn would affect stiffness. However, manipulation of aortic pressure by 
venous return has been shown to produce similar changes in invasively measured PWV as 
pharmacologic manipulation in rats. These findings demonstrate that infusion of vasoactive 
drugs act primarily on the peripheral resistance arteries and do not significantly affect aortic 
smooth muscle tone [25]. 
This protocol can be performed in rats with a few minor modifications. The chest is 
shaved prior to applying depilatory cream. A commercially available 27G x ½” catheter is used 
for drug infusion. The drug doses used to modulate aortic pressure are 40, 80, and 120 µg/kg/min 
PE and 40, 80, and 120 µg/kg/min SNP. 
Besides the ascending aorta, regional differences in aortic stiffness can be determined 
with this protocol. Regional stiffness measured by this approach would be more precise than by 
PWV as measurements are taken from one location as oppose to two locations for PWV. 
However, regions along the aorta that can be measured with this technique are limited to those 
that can be visualized by ultrasound.  
Elastic modulus can also be calculated from the data collected by this method if a wall 
thickness measurement can be obtained. Accurate in vivo measurement of the mouse aorta is 
limited by the resolution limits of current ultrasound technology. Future improvement of 
ultrasound technology could make in vivo wall thickness measurement more feasible. As an 
alternative, thickness measurements can be performed ex vivo. Pressure myography would 
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provide the most accurate measurements because thickness can be measured at each pressure 
increment. 
 
Text reprinted with permission from Kuo MM, Barodka V, Abraham TP, Steppan J, Shoukas 
AA, Butlin M, et al. Measuring ascending aortic stiffness in vivo in mice using ultrasound. J Vis 






















Figure 1.2.1. Longitudinal view of ascending aorta on B-mode. Diameter measurements are 
taken from a longitudinal image of the ascending aorta leaving the left ventricle. LV: left 
ventricle; PA: pulmonary artery; AA: ascending aorta. Visualization of the pulmonary artery 
depends on the probe placement. Aortic diameter is measured distal to the aortic valve. 
Frequency of the probe used to capture this image is 40 MHz. 
 
Figure reprinted with permission from Kuo MM, Barodka V, Abraham TP, Steppan J, Shoukas 
AA, Butlin M, et al. Measuring ascending aortic stiffness in vivo in mice using ultrasound. J Vis 





Figure 1.2.2. Alternate view of ascending aorta on B-mode. The ascending aorta is featured more 
prominently and the left ventricle and heart walls are less distinct. AA: ascending aorta; LV: left 
ventricle. Frequency of probe used to record this image is 40 MHz. 
 
Figure reprinted with permission from Kuo MM, Barodka V, Abraham TP, Steppan J, Shoukas 
AA, Butlin M, et al. Measuring ascending aortic stiffness in vivo in mice using ultrasound. J Vis 












Figure 1.2.3: Aorta visualized on M-mode. Aortic diameter is measured from the M-mode 
image. The movement of the aortic wall appears as two wavy lines. The space in between the 
two lines is the aortic lumen. Systolic and diastolic aortic diameters of three cardiac cycles are 
measured from the M-mode. In this image, aortic pressure recorded by the pressure catheter, 
ECG signal, and respiratory cycle are displayed in red, green, and yellow on the M-mode. Probe 
frequency used to record this image is 40 MHz and the acquisition sweep speed is 1200 Hz. 
 
Figure reprinted with permission from Kuo MM, Barodka V, Abraham TP, Steppan J, Shoukas 
AA, Butlin M, et al. Measuring ascending aortic stiffness in vivo in mice using ultrasound. J Vis 




Figure 1.2.4: Modulating aortic pressure with vasoactive drugs. Aortic pressure is increased with 
infusion of vasoconstrictor phenylephrine (PE) and decreased with infusion of vasodilator 
sodium nitroprusside (SNP). Aortic pressure plateaus 1 minute after the start of the drug 
infusion. M-mode of the aortic diameter is recorded at the plateau. (A) shows the rise in aortic 
pressure with 360 µg/kg/min PE infusion. (B) shows the decrease in aortic pressure with 240 
µg/kg/min SNP infusion. The time the infusion is begun and the time the M-mode is recorded are 
labeled on the traces. 
 
Figure reprinted with permission from Kuo MM, Barodka V, Abraham TP, Steppan J, Shoukas 
AA, Butlin M, et al. Measuring ascending aortic stiffness in vivo in mice using ultrasound. J Vis 





Figure 1.2.5: Changing aortic pressure incrementally. Aortic pressure is changed incrementally 
by the dose of drug infused. Drug dose is modulated by the infusion rate. All doses are in 
µg/kg/min. 
 
Figure reprinted with permission from Kuo MM, Barodka V, Abraham TP, Steppan J, Shoukas 
AA, Butlin M, et al. Measuring ascending aortic stiffness in vivo in mice using ultrasound. J Vis 














Figure 1.2.6: Diameter vs. pressure and compliance vs. mean aortic pressure plots. Aortic 
diameter can be plotted against its corresponding aortic pressure to show the pressure-diameter 
relationship (A). Compliance can be calculated for each pressure increment and plotted against 
the mean aortic pressure (MAP) to show the pressure dependency of aortic stiffness (B). 
 
Figure reprinted with permission from Kuo MM, Barodka V, Abraham TP, Steppan J, Shoukas 
AA, Butlin M, et al. Measuring ascending aortic stiffness in vivo in mice using ultrasound. J Vis 















The prevalence of coronary artery disease after ionizing radiation exposure is well-
documented in the epidemiological literature.  Increased incidence of coronary event has been 
reported in populations exposed to high doses, particularly breast cancer and Hodgkin’s 
lymphoma patients who received radiotherapy [27,28], as well as populations exposed to low 
doses, notably Japanese atomic bomb survivors [29].  These studies showed that the risk of heart 
disease increases proportionally with radiation dose with either no apparent [27] or a very low 
threshold of 0.5 Gy [29].  The mechanisms initiated by ionizing radiation exposure to result in 
the development of coronary artery disease are still not well understood.  Moreover, whether 
these mechanisms are similar to those initiated by traditional risk factors of cardiovascular 
diseases, such as aging, is not firmly established. 
The literature presents some indication that the development of radiation-induced 
coronary artery disease is similar to the progression of coronary artery disease. Coronary artery 
disease is associated with increased aortic stiffness [13],  hypertension [30] and diminished 
coronary vasodilatory function [1], including endothelial-mediated vasodilation [31,32].  These 
markers of coronary artery disease have also been documented in exposed populations.  Greater 
arterial stiffness was reported in Hodgkin’s lymphoma patients who received radiotherapy [33].  
The hypertensive effect of aging was accentuated in Japanese atomic bomb survivors [34].  In 
breast cancer patients who received radiotherapy treatment, vessels in the field of radiation had 
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attenuated endothelial-mediated vasorelaxation whereas non-exposed vessels had intact 
vasodilatory responses [35]. 
On the cellular level, coronary artery disease, and cardiovascular diseases in general, is 
associated with excess reactive oxygen species (ROS) production in the endothelium.  ROS 
scavenges vasodilatory nitric oxide (NO), decreasing NO bioavailability, and leading to 
oxidative stress and endothelial dysfunction [36,37].  Enzymatic sources of ROS associated with 
the development of coronary artery disease have also been reported in radiation-induced vascular 
dysfunction. Patients with coronary artery disease were shown to have augmented activity of 
xanthine oxidase (XO) and increasing XO activity corresponded with decreasing endothelial-
mediated vasodilation [38].  Ionizing radiation exposure was demonstrated to lead to enhanced 
XO activity in large conduit arteries of exposed rats, resulting in elevated ROS level and 
impaired endothelial function [39,40].  Moreover, counteracting augmented ROS production by 
inhibiting the enzymatic source has been demonstrated to improve vascular function in both 
coronary artery disease patients and large conduit arteries of irradiated rats.  Acute intravenous 
administration of XO inhibitor oxypurinol attenuated acetylcholine-induced coronary 
vasoconstriction and increased coronary blood flow in coronary artery disease patients who 
displayed coronary endothelial dysfunction [41].  Acute incubation of aortas from irradiated rats 
with oxypurinol restored endothelial-dependent vasorelaxation. Dietary supplementation of 
oxypurinol also prevented radiation-induced endothelial dysfunction in aortas from exposed rats 
[39,40].  These studies support excess ROS as the common element between coronary artery 
disease and radiation-induced vascular dysfunction. 
 Animal studies on vascular effects of radiation exposure have only been conducted in 
large conduit arteries.  None to date have been conducted in the coronary arteries. We 
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hypothesize that exposure to ionizing radiation induces the same mechanistic events that promote 
the development of coronary artery disease: radiation exposure elevates ROS level in the 
coronary vasculature, leading to impaired coronary endothelial function. We investigate coronary 
vasorelaxation response in vivo one week after a single exposure to 5 Gy ionizing radiation in a 
rat model. We simultaneously measure the systemic parameters that influence coronary function: 
diastolic blood pressure, heart rate and contractility, and aortic stiffness. We further examine 
coronary vasodilatory response ex vivo to investigate endothelial function.  We then consider the 
role of ROS and investigate the use of ROS scavengers and xanthine oxidase inhibitors in 
improving coronary function after radiation exposure. 
 
2.2. METHODS 
2.2.1. Animals and radiation procedure 
All animal use was approved by the Animal Care and Use Committee at Johns Hopkins 
University.  Male, 250-300 g Sprague-Dawley rats (Harlan) were exposed to a single dose of 5 
Gy whole-body gamma radiation using a cesium-137 source (MSD Nordion Gammacell 40) with 
dose rate 0.91 Gy/min.  All in vivo and ex vivo coronary vasoreactivity experiments were 
performed at 1 week after radiation exposure.  In vivo and ex vivo aortic stiffness measurements 
were conducted 1 day and 2 weeks after exposure. 
 
2.2.2. High-resolution transthoracic echocardiography 
Coronary flow velocity and aortic diameter were measured in vivo by ultrasound using a 
15 MHz transducer (Visual Sonics).  The transducer was mounted on a stand (Visual Sonics) to 
record images and Doppler signals from the same location for the duration of the experiment. 
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Rats were anesthetized with 1.5% isoflurane.  Chest hair was removed by shaving followed by 
application of depilatory cream.  The animal was secured onto a heated platform to monitor 
ECG, heart rate, and body temperature.  Drugs were administered intravenously through a 27G 
winged infusion set (Terumo) inserted into the lateral tail vein.  Dose of drug was controlled with 
a syringe pump by adjusting infusion rate (Harvard Apparatus).  All drugs were dissolved in 
0.9% saline. 
 
2.2.3. In vivo coronary vasoreactivity 
The left main coronary artery was visualized from a long axis view by color Doppler 
flow, as described previously [2].  Flow velocity profile of the coronary artery was captured by 
pulse wave velocity.  The difference in angle between blood flow and ultrasound beam was 
accounted for with angle correction on the Vevo mainframe.  Agonist-mediated vasorelaxation 
response was examined by infusing vasodilator adenosine triphosphate (ATP, Sigma) at 20, 40, 
80, and 160 µg/kg/min for 1 minute per dose.  Increasing diameter corresponded with increasing 
flow velocity.  Peak diastolic flow velocity of three cardiac cycles was measured for data 
analysis.   
Metabolic demand-mediated vasorelaxation response was characterized by infusing 
dobutamine (Dob, Hospira) at 5, 10, 20, and 30 ug/kg/min for 2 minutes per dose.  Dobutamine 
challenge was performed twice.  Flow velocity was recorded the first round.  M-mode images of 
the left ventricle were recorded the second round for left ventricular diameter measurement.   
Peak diastolic flow velocities of three cardiac cycles were measured for vasorelaxation 
analysis.  Cardiac contractility was measured as fractional shortening calculated from the end-
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diastolic and end-systolic diameters of three cardiac cycles.  Measurements were done on the 
Vevo 2100 mainframe.   
 
2.2.4. In vivo aortic pressure-diameter relationship 
In vivo stiffness of the ascending aorta was measured as described in Chapter 1.2. 
Ascending thoracic aorta was visualized from a long axis view.  Aortic diameter was recorded 
above the aortic valve by M-mode.  Blood pressure was increased step-wise by infusing 100 
µg/mL phenylephrine (PE, Sigma) at 50, 100, and 200 µL/min at 30 seconds per dose.  After 
return to baseline, blood pressure was decreased step-wise by infusing 100 µg/mL of sodium 
nitroprusside (SNP, Sigma) at 50, 100, and 200 µL/min at 30 seconds per dose.  Diastolic and 
systolic diameters and corresponding blood pressures of three cardiac cycles were measured 
from the M-mode images for each PE and SNP dose.   
Ascending aorta compliance was calculated as described for ex vivo preparations [19]. 
For a constant vessel length, volume within the vessel is proportional to the diameter squared.  
The equation for vessel compliance therefore becomes C = ∆V / ∆P = ∆ D
2
 / ∆P, where C is 
compliance, ∆V is change in volume, ∆P is change in pressure, and ∆ D
2
 is change in squared 
diameter.  Aortic diameter squared was plotted against the corresponding blood pressure and a 
line was fitted to the resulting plot using a linear least squares-fit algorithm (GraphPad).  The 
slope of the fitted line was used as a measure of aortic compliance.   
 
2.2.5. Invasive aortic blood pressure measurement 
A 1.2F solid-state catheter (Transonic) was inserted into the right femoral artery and 
advanced into the abdominal aorta.  Signal output from the pressure control unit was split with a 
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BNC splitter.  One output was connected to the Powerlab and LabChart data acquisition system 
(AD Instruments) for real-time display of blood pressure.  The second output was connected to 
the high-resolution ultrasound system (Vevo 2100, Visual Sonic) for simultaneous recording of 
blood pressure with ultrasound measurements.  Aortic pressure was measured in a separate set of 
animals for the coronary vasoreactivity challenges and simultaneously for the in vivo aortic 
stiffness measurements. 
 
2.2.6. Aortic tensile testing 
Following in vivo stiffness measurement, rat was euthanized by exsanguination and the 
aorta was harvested and cleaned.  Ring sections were cut from the ascending aorta.  Aortic rings 
were imaged and ring length and inner and outer diameters were measured with ImageJ 
(National Institute of Health).  The sample was mounted onto two pins of a tissue puller (Danish 
Myo Technology).  The ring was pulled apart to material failure and the force generated by 
displacement was recorded on the system’s data acquisition software.  Displacement was 
converted to strain by normalizing to the inner diameter of the ring.  Force was converted to 
stress by dividing measured force by cross-sectional area of the vessel wall, calculated as the 
product of wall thickness and ring length.  Because the recorded strain values were different for 
each sample, the stress-strain plot of each sample was fitted with an exponential curve on Prism 
(GraphPad).  A new set of stress values was then calculated from the fitted equation using a set 
of strain values that was used for every sample.  
 
2.2.7. Ex vivo coronary vasoreactivity 
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Rats were euthanized by isoflurane overdose and left main and descending coronary 
artery was dissected and sectioned into ~1mm rings. Precise vessel section length was measured 
and vessel sections were mounted onto a wire myograph (DMT). Vessels were bathed in 95/5% 
O2/CO2 oxygenated Krebs physiological solution containing in [mM] 118 NaClm 4.7 KCl, 25.0 
NaHCO3, 1.2 MgSO4, 1.1 KH2PO4, 11 glucose, and 2.5 CaCl2-2H2O maintained at 37C. 
Vessels were equilibrated for 30 minutes and then stretched in 0.3 mN increments to the tension 
equivalent to 50 mmHg (6.7 kPa), as determined by the DMT normalization module for 
LabChart. After stretching, vessels were equilibrated for 15 minutes, and then subjected to two 
rounds of 60mM KCl bolus injection into the bath.  
Rings were pre-constricted with 10
-6
 M prostaglandin F2α (Cayman Chemicals) or 10
-6.5
 
M prostaglandin H2 analog U46619 (Cayman Chemicals).  Cumulative doses of acetylcholine 
(Ach, Sigma Aldrich) and sodium nitroprusside (SNP, Sigma Aldrich) were added to evaluate 
endothelial-dependent and –independent vasorelaxation.  Relaxation tensions were normalized to 
pre-constriction tension for data analysis. 
In a separate set of experiments, coronary rings were pre-constricted with U46619 and 
once a steady pre-constriction was reached, further constricted with the addition of 100 µM of 
nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester (L-NAME, Cayman Chemicals). 
Increase in constriction tension was measured as the percent increase in coronary tone after the 
addition of L-NAME compared to the U46619-induced pre-constriction tension. 
 
2.2.8. In vitro measurement of total reactive oxygen species (ROS) content 
Left main and descending coronary arteries were harvested and snap frozen at 2 weeks 
post-irradiation.  Frozen samples were homogenized in radioimmunoprecipitation assay (RIPA, 
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Upstate) with protease inhibitor buffer.  Total reactive oxygen species (ROS) was measured in 
the homogenate with the OxiSelect In Vitro ROS/RNS Assay Kit (Cell Biolabs, Inc.), following 
the manufacturer’s directions.  Homogenate was incubated with 100 µM and 500 µM superoxide 
dismutase mimetic, manganese (III) tetrakis (4-benzoic acid) porphyrin (MnTBAP, CalBiochem) 
or 1mM oxypurinol (Oxp, Sigma).  ROS content was measured in terms of ROS production rate 
and normalized to the amount of protein.  Data is expressed as relative fluorescent unit 
(RFU)/min/mg protein. 
 
2.2.9. In vivo testing of ROS and its enzymatic sources 
 Rats were administered an intravenous bolus infusion of 1 mg/kg MnTBAP, 10 mg/kg 
oxypurinol, or 10 mg/kg of an alternate XO inhibitor, allopurinol (Allo, Sigma).  Basal and ATP-
induced increase in flow velocity measurements were taken two minutes after infusion for 
MnTBAP treatment and 15 minutes after infusion for oxypurinol and allopurinol treatments. 
 
2.2.10. Statistical analysis 
Statistical significance was determined by Student’s t-test or two-way analysis of 
variance with Bonferroni post-test using Prism (GraphPad).  Data are reported as mean±SEM. 
 
2.3. RESULTS 
2.3.1. In vivo coronary vasoreactivity 
We first characterized coronary vasodilatory function after radiation exposure. At one 
week post-irradiation, ATP-induced increase in flow velocity was diminished in 5 Gy rats 
(p<0.001, Fig. 2.1A). Metabolic demand-induced increase in flow velocity was also attenuated in 
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5 Gy rats (p<0.001, Fig. 2.1B). Flow velocity at dobutamine dose 30 µg/kg/min was 957.3±18.2 
mm/s in 0 Gy compared 815.7±56.3 mm/s in 5 Gy, p<0.01. Corresponding diastolic aortic 
pressure was also significantly reduced for both ATP (p<0.001, Fig. 2.1C) and dobutamine 
responses (p<0.001, Fig. 2.1D). 
 We next considered the influence of cardiac function on coronary flow through heart rate 
and contractility. Heart rate was lower in 5 Gy rats for both ATP (p<0.001, Fig. 2.2A) and 
dobutamine responses (p<0.001, Fig. 2.2B). Contractility response to dobutamine was enhanced 
in 5 Gy rats (p<0.01, Fig. 2.2C). Fractional shortening at 30 µg/kg/min dobutamine was 
61.4±2.9% in 0 Gy compared to 76.2±1.7% in 5 Gy rats, p<0.01. 
We further investigated if changes in aortic stiffness occurred with radiation exposure. In 
vivo ascending aortic stiffness in 5 Gy rats increased 1 day after exposure and returned to 0 Gy 









/mmHg, p=0.020. At 2 weeks, 




/mmHg, p=0.016 compared to 1 day 
stiffness.  Ex vivo measurement of ascending aortic stiffness showed no changes in stiffness at 1 
day or 2 weeks post-radiation exposure (Fig. 2.3B). 
 
2.3.2. Ex vivo coronary vasoreactivity 
To determine if decreased coronary tone observed in vivo was due to impaired coronary 
vasodilatory function, we examined coronary vasoreactivity ex vivo by wire myography. No 
change in endothelial-dependent relaxation was observed one week after radiation exposure (Fig. 
2.4A). However, endothelial-independent relaxation was enhanced (p<0.05, Fig. 2.4B). Pre-
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constriction tone normalized to vessel length and L-NAME-induced increase in pre-constriction 
tone were not different between cohorts (Fig. 2.4C).  
 
2.3.3. Coronary ROS level and NO bioavailability 
We next considered NO availability in the coronary artery after radiation exposure with 
in vitro ROS measurement and basal coronary flow. Coronary ROS level 2 weeks post-exposure 
was greater in coronary arteries of 5 Gy rats than of 0 Gy rats: ROS amount was 1999.7±347.3 
ROS/mg protein in 0 Gy compared to 4802.6±1141.6 ROS/mg protein in 5 Gy rats, p = 0.047 
(Fig. 2.5A).  Incubation with MnTBAP reduced ROS amount in both 0 Gy and 5 Gy groups.  
ROS abundance was not different between cohorts after incubation with 100 µM and 500 µM 
MnTBAP. 500 µM MnTBAP significantly reduced ROS in the 5 Gy coronary arteries: ROS 
content was 1471.7±183.0 ROS/mg protein with 500 µM MnTBAP compared to 4802.6±1141.6 
ROS/mg protein in untreated vessels, p=0.026. Incubation with 1 mM oxypurinol (Oxy) did not 
change ROS content in the 0 Gy group but reduced ROS in the 5 Gy group to 0 Gy level (p = 
0.089): ROS amount was 2632.3±282.2 ROS/mg protein in Oxy-incubated 5 Gy coronary tissue 
compared to 2699.3±511.5 ROS/mg protein in Oxy-incubated 0 Gy tissue.   
NO bioavailability was further examined in vivo by measuring changes in basal coronary 
flow with infusion of ROS scavengers and inhibitors (Fig. 2.5B). Basal coronary flow velocity 
was significantly lower in 5 Gy rats than in 0 Gy rats: flow velocity was 356.8±13.3 mm/s in 5 
Gy compared to 463.6±13.2 mm/s in 0 Gy, p=0.0001.  MnTBAP infusion increased basal flow 
velocity in 5 Gy rats to the level of 0 Gy rats: flow velocity was 507.0±23.3 mm/s in MnTBAP-
infused 5 Gy animals compared to 356.8±13.3 mm/s in untreated 5 Gy animals, p <0.0001.  
Xanthine oxidase inhibitor allopurinol (Allo) partially restored baseline flow: 411.3±18.17 mm/s 
43 
 
in Allo-treated 5 Gy rats compared to 356.8±13.34 mm/s in untreated 5 Gy rats, p = 0.044.  
Oxypurinol also increased basal flow velocity in 5 Gy to a similar extent as allopurinol, although 
the difference was not statistically significant: 404.0±42.2 mm/s with oxypurinol treatment 
compared to 356.8±13.3 mm/s without treatment in 5 Gy, p=0.085.   
We sought to determine if in vivo coronary vasodilatory response was similarly 
improved.  Although acute XO inhibition improved resting tone, it did not improve vasodilatory 
response.  ATP-mediated vasorelaxation with allopurinol (Fig. 2.6A) and oxypurinol (Fig. 2.6B) 
treated 5 Gy rats were not statistically different than untreated 5 Gy rats. 
 
2.4. DISCUSSION 
This study is the first to investigate the effects of radiation exposure in the coronary 
artery. Our data show that single whole-body exposure to 5 Gy ionizing radiation reduces 
coronary flow in vivo. The reduced coronary flow is attributed to a combination of decreased 
diastolic aortic pressure and excess scavenging of NO by ROS.  Endothelial-mediated 
vasodilatory function and eNOS activity, however, remain intact after radiation exposure. The 
data support that elevated ROS is the initial sign of radiation injury and precedes endothelial 
dysfunction that lead to later development of coronary artery disease.  
The reduced flow velocity observed in vivo in 5 Gy rats could arise from increased 
coronary tone and impaired vasodilatory capacity or reduced coronary perfusion pressure. We 
first considered the influences of perfusion pressure. Examination of coronary perfusion pressure 
through aortic diastolic pressure showed that diastolic pressure was reduced in 5 Gy rats. We 
next investigated whether radiation exposure altered the systemic parameters that influence 
diastolic pressure, namely heart rate and aortic stiffness.  We found that heart rate was also lower 
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in 5 Gy rats.  The restoration of in vivo aortic stiffness from one day post-irradiation to two 
weeks post-irradiation support that stiffness at one week was not increased enough to 
appreciably influence diastolic pressure.  Tensile testing data further showed that tensile 
properties of the aortic wall did not change over the two week period, indicating that wall 
remodeling and changes to aortic wall content did not occur within two weeks after radiation 
exposure.  Taken together, the data show that the decreased flow velocity observed in vivo can 
be attributed to reduced diastolic pressure.  Reduced diastolic pressure appears to be 
predominantly due to changes in heart rate and not aortic stiffness, suggesting that radiation has 
direct effects on heart function.   
We next considered if the reduced in vivo coronary flow was also the result of impaired 
vasodilatory function. Endothelial-mediated vasorelaxation response was not different between 0 
Gy and 5 Gy rats. However, endothelial-independent vasorelaxation response to NO donor SNP 
was enhanced, supporting that coronary arteries of 5 Gy rats exhibited increased sensitivity to 
NO.  If production of NO was reduced, the enhanced NO sensitivity could compensate to some 
extent for the decrease in NO, resulting in intact endothelial-mediated vasorelaxation.  We 
determined if eNOS activity and therefore NO production was impaired by evaluating U46619 
pre-constriction tone and L-NAME-induced increase in pre-constriction tone.  Pre-constriction 
tone is a balance between the vasoconstrictive effects of the pre-constricting agent and the 
vasodilatory mediators that are produced basally by the endothelium.  Reduction of basal 
production of vasodilatory mediators, including NO, results in increased pre-constriction tone 
and has been previously shown experimentally with NO production cessation by L-NAME [42].  
Addition of L-NAME after the coronary artery reaches a steady pre-constriction tone would 
similarly increase pre-constriction tension. Our data showed that U46619 pre-constriction tone 
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when normalized to vessel length was not different between 0 Gy and 5 Gy animals, supporting 
that basal production of vasodilatory mediators was not impaired. This finding is further 
corroborated by the similar L-NAME-induced percent increase in pre-constriction tone between 
the cohorts.  
While the reduced coronary flow observed in vivo was not associated with impaired 
coronary endothelial-mediated vasodilatory function or eNOS activity, it could potentially be 
explained by reduced NO bioavailability.  In vitro measurement of ROS level in the coronary 
tissue showed elevated superoxide level, supporting reduced NO bioavailability from excess 
ROS-mediated scavenging.  Because NO is the primary vasoactive mediator of baseline coronary 
tone [43,44], basal coronary flow can also be used as a measure of NO bioavailability.  Changes 
in in vivo baseline coronary flow with administration of ROS scavengers and ROS producer 
inhibitors were consistent with in vitro ROS measurements. 5 Gy rats exhibited reduced basal 
coronary flow, which supports diminished NO bioavailability, as well as elevated superoxide 
content in vitro, which supports excess scavenging of NO.  Bolus infusion of MnTBAP raised 
coronary flow, as in vitro incubation with MnTBAP reduced coronary ROS. Acute 
administration of xanthine oxidase inhibitors oxypurinol and allopurinol partially restored 
baseline coronary flow in 5 Gy rats, consistent with the partial reduction of ROS content in vitro 
with oxypurinol incubation.  Together, the data support that ROS content in the coronary artery 
is increased after radiation exposure and that NO bioavailability is reduced because of excess 
ROS scavenging. 
The findings of this study are particularly intriguing when considering the long latency 
period between diagnosis of coronary artery disease and radiation exposure.  The mean time of 
diagnosis of coronary artery disease symptoms in cancer patients who underwent radiation 
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therapy is 7 years after treatment [45].  Furthermore, epidemiological and patient studies 
investigating vascular effects of radiation exposure are conducted several years after the patients 
underwent treatment.  The presence of physiological dysfunction years after radiation exposure 
could indicate that initial radiation exposure causes direct endothelial injury and that vascular 
damage is sustained.  Or, as the long latency period suggests and this study supports, radiation-
induced vascular dysfunction is progressive.  Radiation-associated cardiovascular disease is not 
due to direct cellular damage from the radiation exposure, but, appears to be analogous to aging-
associated vascular diseases. Vascular aging is characterized by endothelial dysfunction that is 
initiated by elevated superoxide production and subsequent scavenging of NO [46].  Our data 
support that radiation-associated coronary artery disease is similarly initiated by augmented 
superoxide release which leads to excess NO scavenging and eventually results in coronary 
endothelial dysfunction characteristic of coronary artery disease. 
Although inhibition of xanthine oxidase partially restored baseline flow in 5 Gy rats, it 
did not restore coronary flow.  In the patient study that showed improvement in coronary 
function with acute oxypurinol treatment, endothelial-mediated vasorelaxation was improved 
with treatment in coronary artery disease patients who exhibited impaired coronary endothelial 
function [41].  The treatment had no effect in patients who had intact coronary endothelial 
function.  Endothelial-mediated vasorelaxation and eNOS activity were intact in 5 Gy rats, 
supporting that endothelial function was preserved.  Xanthine oxidase inhibitor treatment 
therefore had no effect in 5 Gy rats because these rats did not display impaired coronary 
endothelial function.   
 Phenotypical changes in the coronary artery after radiation exposure appear similar to 
aging. However, cardiac function after radiation exposure does not.  Cardiac function diminishes 
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with age and is associated with reduced β-adrenergic responsiveness arising from a combination 
of decreased expression of β-adrenergic receptors, decreased agonist binding, and dysregulated 
downstream signal transduction [47].  The reduced heart rate observed in this study could 
therefore be due to a reduction in β-adrenergic receptor expression or impaired receptor function.  
However, rabbits exposed to 5 Gy whole-body X-ray radiation only exhibited a slight decrease in 
expression and binding affinity of β-adrenergic receptors at 3 days that tended towards non-
irradiated values by 7 days [48].  The reduced heart rate observed in this study therefore does not 
appear to be a result of reduced receptor expression or binding affinity.  Dysregulated 
downstream signaling could also result in decreased heart rate. However, contractility data 
showed enhanced contractility in 5 Gy rats, suggesting enhanced responsiveness of β-adrenergic 
signaling. Changes in cardiac function therefore appear to occur by mechanisms different than 
those that occur with aging.  
The aortic stiffness data reported in this study conflicts with a previous study by Soucy et 
al. [39] that reported an increase in aortic stiffness one day after exposure to 5 Gy gamma 
radiation that remained sustained at 2 weeks post-irradiation.  The radiation source and rat strain 
used in this study were the same as the Soucy et al. study.  Discrepancy in findings could be 
attributed to different measurement methodologies.  Soucy et al. measured aortic stiffness by 
pulse wave velocity while this study measured aortic stiffness from the pressure-diameter 
relationship and by tensile testing.  More likely, however, the discrepancy is due to the difference 
in age of the rats at the time of radiation exposure.  Rats used in this study were 2 months old 
while the rats used in the Soucy et al. study were 3-4 months.  Epidemiological studies have 
shown that age at radiation exposure influences likelihood of future cardiovascular event.  When 
the risk of major coronary event in breast cancer patients who had received radiotherapy was 
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stratified by age, risk of major coronary event was dramatically less in women age 20-39 at the 
time of diagnosis than in women 40 and above [27].  Although the confidence interval was very 
wide for this age group, the influence of age at the time of radiotherapy on the risk of future 
cardiovascular events has been reported in other studies.  The effect of radiation exposure on 
aortic and carotid artery stiffness in Hodgkin’s lymphoma patients who had undergone 
radiotherapy was more pronounced in patients who were treated at age 40 and above [33].  2-
month old rats were used in this study because the left coronary artery was easier to locate than 
in than 3-month old rats. This discrepancy in findings highlights the importance of age at the 
time of radiation exposure and support the epidemiological literature that suggests a younger 


















Figure 2.1. Coronary vasoreactivity in vivo. Coronary vasodilatory function was evaluated in 
vivo using high-resolution ultrasound. Vasorelaxation function was assessed in terms of agonist-
mediated vasorelaxation with vasodilator adenosine triphosphate (ATP) and myocardial demand-
mediated vasorelaxation with β-adrenergic receptor agonist dobutamine (Dob). Increase in 
coronary artery diameter was reflected in an increase in coronary flow velocity.  5 Gy rats 
exhibited attenuated ATP-mediated (A) and metabolic demand-mediated (B) vasorelaxation 
response, ***p<0.001.  Diastolic aortic pressure was used to evaluate coronary perfusion 
pressure.  5 Gy rats exhibited reduced diastolic pressure during the ATP (C) and dobutamine (D) 
challenges.  Drug doses are in units of µg/kg/min. 












































































































Figure 2.2. Cardiac parameters that influence coronary flow. Heart rate and cardiac contractility 
were measured to determine if changes in cardiac function could account for the decreased 
coronary flow. 5 Gy rats exhibited reduced heart rate during ATP (A) and dobutamine (Dob) (B) 
challenges, ***p<0.001. Cardiac contractility, measured as fractional shortening (C), was 












































































Figure 2.3. In vivo and ex vivo ascending aorta stiffness. Aortic stiffness was measured to 
determine if ionizing radiation induced changes in stiffness that would in turn influence coronary 
perfusion pressure and coronary flow. Stiffness of the ascending aorta was determined in vivo 
from its pressure-diameter relationship measured by ultrasound imaging and invasive 
measurement of aortic pressure. Aortic stiffness was measured ex vivo by tensile testing.  5 Gy 
rats exhibited decreased in vivo compliance, indicating increased stiffness, at 1 day post-
irradiation that returned to 0 Gy value by 2 weeks post-irradiation, *p<0.05 (A). Ex vivo stiffness 
measured by tensile testing showed no difference between 0 Gy and 5 Gy aortas over the 2 week 
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Figure 2.4.  Coronary vasoreactivity ex vivo. Coronary endothelial function was measured ex 
vivo by wire myography. 5 Gy rats exhibited similar endothelial-mediated vasorelaxation 
response as 0 Gy rats (A). However, 5 Gy rats also displayed enhanced endothelial-independent 
nitric oxide-mediated vasorelaxation response (B), *p<0.01.  eNOS activity was evaluated by 10
-
6.5 
M U46619 pre-constriction tone normalized to vessel ring length and 100 µM NOS inhibitor 
L-NAME induced percent increase in pre-constriction tone. Both pre-constriction tone and L-
NAME enhanced tone were not different between cohorts (C). 
 
 







































































Figure 2.5. In vitro and in vivo assessment of NO bioavailability.  ROS content and in vivo basal 
coronary flow were measured to evaluate NO bioavailability.  In vitro measurement of ROS 
content showed that coronary arteries from 5 Gy rats had significantly higher ROS content than 
coronary arteries from 0 Gy rats (A). Incubation with 500 µM superoxide scavenger MnTBAP, 
reduced ROS content in 5 Gy arteries significantly, #p<0.05 between 5 Gy and 5 Gy + 500 µM 
MnTBAP. Inhibition of ROS production by xanthine oxidase inhibition with 1 mM oxypurinol 
(Oxy) partially reduced ROS content in 5 Gy coronary arteries.  In vivo assessment of NO 
bioavailability by baseline flow velocity showed that 5 Gy rats had significantly reduced baseline 
flow velocity compared to 0 Gy rats (B).  Acute infusion of 1 mg/kg MnTBAP dramatically 
increased basal flow in 5 Gy rats whereas acute infusion of xanthine oxidase inhibitors 































































































Figure 2.6. Effectiveness of ROS production inhibition on restoring in vivo coronary vasodilatory 
function.  Xanthine oxidase inhibitors were administered to determine if xanthine oxidase 
inhibition could improve coronary flow in 5 Gy rats. Neither 10 mg/kg allopurinol (A) or 10 

































































CHAPTER 3: MPST AND  NOT CSE IS THE PRIMARY REGULATOR OF 




Coronary tone is regulated by the endothelium predominantly through vasodilatory 
mediators nitric oxide (NO) and endothelial-derived hyperpolarizing factors (EDHFs).  NO is 
produced by endothelial nitric oxide synthase (eNOS) and has been demonstrated to regulate 
resting coronary tone [49,50] and metabolic demand-mediated vasodilation [51].  Of the 
EDHFs, hydrogen peroxide (H2O2) has been widely researched.  H2O2 has similarly been shown 
to be involved in coronary autoregulation [52], metabolic demand-mediated vasodilation [53], 
and flow-mediated vasodilation [54].  
Another EDHF, hydrogen sulfide (H2S), has recently emerged as another important 
gasotransmitter in the vasculature. H2S is produced from L-cysteine by cystathionine gamma-
lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (MPST) [55]. CSE converts L-cysteine 
into H2S with pyridoxal-5’-phosphate (PLP) as a cofactor.  L-cysteine-dependent production of 
H2S by MPST is a two-step reaction. First, cysteine aminotransferase converts L-cysteine along 
with α-ketoglutarate into 3-mercaptopyruvate (3-MP). MPST then converts 3-MP into H2S [56]. 
CSE appears to have an important role in vascular tone regulation as mice lacking CSE are 
hypertensive and have attenuated endothelial-dependent vasodilation [57].   
Vasoactive effects of H2S vary by vascular bed.  In the mesenteric bed, H2S is a 
vasodilator [58] while in the pulmonary bed, it is a vasoconstrictor [59].  In the aorta, the 
vasoactive effect of H2S depends on dose [60]: H2S is a vasoconstrictor at low doses and a 
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vasodilator at high doses.  In the coronary vasculature, H2S has been reported to be a vasodilator 
[61], [62].  H2S induces coronary vasodilation independent of the endothelium through 4-
aminopyridine-sensitive Kv, BKCa, and KATP channels [61-64].  The role of CSE as a producer of 
endogenous H2S has also been investigated, although conclusions regarding its contribution are 
inconsistent.  Some studies support little contribution of CSE in coronary vasoregulation [61,64] 
while others support involvement [62,63]. 
The role of MPST in coronary vasoregulation has not been examined. Moreover, the 
current literature on H2S involvement in coronary vasoregulation lacks direct measurement of 
H2S production in the coronary artery.  In this study, we hypothesized that MPST is a source of 
endogenous H2S in the coronary vasculature. We measured protein abundance of the two H2S 
producing enzymes and measured in vitro H2S production through both pathways. We next 
investigated the role of CSE-derived H2S in vivo by measuring in vivo coronary vasorelaxation 
function in CSE inhibited and CSE knockout models. We then investigated the role of MPST-





All animal use was approved by the Animal Care and Use Committee at Johns Hopkins 
University.  In vivo coronary vasoreactivity experiments were performed in male, 12-18 week 
old CSE-deficient (CSE-/-) and B6129S (Jackson) wild-type mice. Male. 250-300g Sprague-




3.2.2. Cell culture 
Human coronary artery (HCAECs, Lonza) and aortic endothelial cells (HAECs, Lonza) 
were cultured in endothelial basal medium supplemented with 5% fetal bovine serum, 
endothelial cell growth supplements, and penicillin/streptomycin (Lonza). 
 
3.2.3. Protein expression 
Protein expression was determined in human endothelial cells and rat vascular tissue by 
Western blot. Rat aorta and left coronary artery were harvested for analysis. Cells were lysed and 
tissue was homogenized in 1X radioimmunoprecipitation assay (RIPA) buffer (Upstate) 
containing protease inhibitors (Roche). Antibodies used were rabbit-polyclonal anti-MPST 
antibody (1:1000, Atlas Antibody), rabbit-polyclonal anti-CSE antibody (1:1000, ProteinTech) 
for human endothelial cells, and mouse-monoclonal anti-CSE antibody (1:1000, ProteinTech) for 
rat tissue.  Mouse-polyclonal anti-GAPDH antibody was used as loading control (1:5000, Novus 
Biologicals).  HRP-conjugated donkey anti-rabbit or sheep anti-mouse secondary antibody 
(1:5000, GE Healthcare) was used for detection. Blots were developed using SuperSignal West 
Pico Chemiluminescent Substrate (ThermoScientific). HAECs and rat aorta were used as 
positive controls. 
 
3.2.4. In vitro amperometric H2S measurement 
Tissue H2S production was measured by amperometry using the Apollo 4000 Free 
Radical Analyzer detector (WPI) and a 3-mm H2S-selective electrode (WPI).  Reactions were 
performed as previously described [55].  For MPST-mediated H2S production, rat liver and 
coronary tissue samples were homogenized in cold 10X PBS buffer containing 1 mM 
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dithiothrietol (DTT; New England BioLabs) and protease inhibitor (Roche). Total reaction 
volume was 200 µL and total protein amount used was 300 µg for liver and 30 µg for coronary. 
Homogenate was incubated with MPST substrate 3-mercaptopyruvate (3-MP; Sigma) for 50 
minutes at 37°C in 2 mL gas-tight vials (Fisher).  Liver homogenate was incubated with the 
listed 3-MP concentrations. Coronary homogenate was incubated with 1 mM 3-MP.  After 50 
minutes of incubation, 200 µL of 10X PBS adjusted to pH 6.0 was added to the reaction to 
promote release of H2S and to stop the reaction. The reaction was incubated at 37°C for another 
10 minutes. 2 mL of headspace for liver samples and 3 mL of headspace for coronary samples 
was withdrawn from the gas-tight vial using a 10 mL syringe (BD) with a 22 G needle (BD) 
attached and injected into a scintillation vial containing 15 mL of 10X PBS (ThermoScientific) 
in which the amperometric probe was equilibrating. Amount of H2S produced by the reaction 
was measured by the probe in units of pA. Data was recorded two minutes after the headspace 
gas was injected.  
For CSE-mediated H2S production, the tissue was homogenized in 10X PBS buffer 
containing protease inhibitor and incubated with 2 mM pyridoxal-5’-phosphate (PLP; Sigma) 
and L-cysteine (Sigma) [65].  Liver homogenate was incubated with listed L-cysteine 
concentrations. Coronary homogenate was incubated with 50 mM L-cysteine. Reaction 
incubation and measurement procedures were performed as described. 
Experiments were done in triplicate. H2S produced from liver homogenate was measured 
as the difference in amperometric signal between the liver homogenate incubated with the 
indicated substrate concentration and baseline signal of the homogenate with no substrate.  H2S 
produced by the coronary tissue was calculated as the difference between the substrate incubated 
with coronary homogenate and baseline signal of the substrate incubated with no protein 
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homogenate. A calibration curve for the amperometric probe was generated using H2S donor 
sodium hydrosulfide (NaHS) and assuming that 1/3 of NaHS is in soluble H2S form [66] to 
equate pA units to H2S concentration. 
 
3.2.5. In vitro fluorimetric H2S measurement 
Fluorometric measurement of H2S was performed using 7-Azido-4-Methylcoumarin 
(AzMC; Sigma). Reactions were carried out in 1X PBS (Invitrogen) in a black 96-well plate with 
total reaction volume of 100 µL. To determine NO-H2S reactivity, increasing concentration of 
NO donor sodium nitroprusside (SNP) was added to 10
-3
 M NaHS and allowed to react for 1 
min. 50 µM AzMC was then added and incubated for 5 minutes at room temperature. 
Fluorescence intensity was measured by SpectraMax Gemini EM plate reader (Molecular 
Devices) at 365 nm excitation and 450 nm emission. Reactivity of AzMC to H2S was confirmed 
by adding 50 µM AzMC to increasing NaHS concentrations, as listed. 
 
3.2.6. In vivo coronary vasoreactivity 
Coronary tone was evaluated in vivo by measuring coronary flow velocity using 
transthoracic echocardiography as previously described [67].  Mice were anesthetized with 1.5% 
isoflurane and coronary flow velocity was measured using the Vevo 2100 (Visual Sonics) and a 
40 MHz transducer (Visual Sonics).  The transducer was mounted on a stand (Visual Sonics) to 
measure flow velocity from the same location for the entire experiment.  Chest hair was removed 
by depilatory cream.  The animal was secured onto a heated platform to monitor ECG, heart rate, 
and body temperature.   
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Left main coronary artery was visualized by color Doppler flow from a modified long 
axis view of the left ventricle.  Flow velocity profile of the blood flow through the coronary 
artery was captured by pulse wave velocity.  The difference in angle between blood flow and 
ultrasound beam was accounted for with angle correction done on the Vevo mainframe. 
Coronary vasorelaxation was induced by intravenous transfusion of adenosine 
triphosphate (ATP, Sigma) or beta-adrenergic agonist dobutamine (Dob, Hospira). ATP was 
administered to evaluate agonist-induced coronary vasorelaxation and dobutamine to evaluate 
metabolic demand-mediated vasorelaxation.  Increase in diameter corresponded with an increase 
in flow velocity.  Drugs were infused through a catheter inserted into the lateral tail vein.  
Catheters were custom-made by attaching a 30 gauge needle (BD) to size PE-10 polyethylene 
tubing (BD).  Dose of drug administered was controlled with a syringe pump (Harvard 
Apparatus) by adjusting infusion rate.   
Working concentration of ATP was 0.5 mg/mL. ATP was infused at 20, 40, 80, and 160 
µg/kg/min for 1 minute per dose.  Coronary flow velocity was allowed to return to baseline 
between each dose.  Working concentration of dobutamine was 0.2 mg/mL.  Dobutamine was 
infused at 5, 10, 20, and 30 µg/kg/min at 2 minutes per dose.  CSE inhibitor propargylglycine 
(PPG, Sigma) dissolved in saline was administered intravenously at 50 mg/kg 30 minutes before 
flow velocity measurements. All drugs were prepared in a heparinized 0.9% saline solution.  
Peak diastolic flow velocities of three cardiac cycles were measured for data analysis. 
 
3.2.7. Wire myography 
Rats were euthanized by isoflurane overdose and left main and descending coronary 
artery was dissected and sectioned into ~1 mm rings. Precise vessel section length was measured 
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and vessel sections were mounted onto a wire myograph (DMT). Vessels were bathed in 95/5% 
O2/CO2 oxygenated Krebs physiological solution containing in [mM] 118 NaCl, 4.7 KCl, 25.0 
NaHCO3, 1.2 MgSO4, 1.1 KH2PO4, 11 glucose, and 2.5 CaCl2-2H2O maintained at 37°C. 
Vessels were equilibrated for 30 minutes and then stretched in 0.3 mN increments to the tension 
equivalent to 50 mmHg (6.7 kPa), as determined by the DMT normalization module for 
LabChart. After stretching, vessels were equilibrated for 15 minutes, and then subjected to two 





 M U46619 (Cayman) for 15 minutes. Vessels were then subjected to cumulative dose 












 M; Sigma).  
To test the involvement of arachadonic acid, rings were next incubated with 10 µM 
phospholipase A2 inhibitor 4-4(-octadecylphenyl)-4-oxobutenoic acid (OBAA; Tocris) for 30 
minutes prior to U46619 pre-constriction,  and NaHS and 3-MP dose responses were carried out. 
Rings were then incubated with 100 µM L-NG-nitroarginine methyl ester (L-NAME; Caymen) 
to test nitric oxide synthase involvement for 15 minutes prior to U46619 pre-constriction. In a 
separate experiment, coronary artery rings were mechanically denuded to examine the role of the 
endothelium in H2S and 3-MP mediated response. 
Acetylcholine (Ach; Sigma) 10
-5
 M was added after NaHS 10
-3
 M and 3-MP 10
-4
 M to 
determine if endothelial-mediated vasorelaxation function remained intact. In separate 
challenges, vessels were pre-constricted with U46619 and after steady constriction was reached, 
100 µM L-NAME was added. After a steady L-NAME-induced constriction was reached, Ach 
10
-5
 M was added to evaluate endothelial-mediated vasorelaxation after NOS inhibition. 
 
3.2.8. Statistical analysis 
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Statistical significance was determined by two-way analysis of variance with Bonferroni 
post-test or Student’s t-test (GraphPad).  Data is reported as mean±SEM. 
 
3.3. RESULTS 
3.3.1. CSE and MPST expression in the coronary artery 
CSE expression varied between human endothelial cell lines: expression was robust in 
HAECs and minimal in HCAECs in comparison (Fig. 3.1A).  Both cell lines expressed eNOS 
and MPST in similar abundance. 
In rat tissue, CSE was expressed in similar abundance in coronary artery and aorta (Fig. 
3.1B). MPST was also expressed in both, although expression was more robust in aortic tissue. 
Similar abundance of GAPDH confirms equal protein loading between samples. 
 
3.3.2. MPST and CSE-mediated H2S production in coronary tissue 
Enzymatic kinetics of MPST and CSE was characterized in rat liver, where both enzymes 
are robustly expressed [68,69].  Km value of MPST for 3-MP in the reaction conditions was 
0.46±0.08 mM 3-MP and Vmax was 254.1±9.6 nM H2S (Fig. 3.2A). Vmax of CSE for L-
cysteine was not reached for the conditions tested so Km of CSE could not be determined (Fig. 
3.2B). 
To induce maximum enzyme activity, coronary artery homogenate was incubated at 
twice the Km value for 3-MP and at the highest L-cysteine concentration evaluated. H2S 
produced in these conditions were 32.4±6.1 nM for 3-MP incubation and 3.6±6.5 nM for L-





3.3.3. Role of CSE-derived H2S in coronary vasorelaxation in vivo 
ATP-mediated vasorelaxation (Fig. 3.3A) was not different between WT, WT treated 
with PPG, and CSE -/- mice (p=0.33 for WT vs. PPG-treated and p=0.31 for WT vs. CSE -/-).  
Metabolic demand-mediated vasorelaxation induced by dobutamine (Fig. 3.3B) was also not 
different between cohorts (p=0.66 for WT vs. PPG-treated and p=0.23 for WT vs. CSE -/-). 
 
3.3.4. Vasoactive effects of exogenous H2S and 3-MP 
3-MP caused dose-dependent vasoconstriction in coronary rings (Fig. 3.4A): 10
-6
 M 
decreased pre-constriction tone by 3.6±2.2% while 10
-5
 M significantly increased pre-
constriction tone by 19.7±9.5% (p=0.022 compared to 3-MP 10
-6
 M), and 10
-4
 M increased pre-
constriction tone by 68.6±26%. (p=0.059 compared to 3-MP 10
-5
 M). Vasoconstrictive response 
to 3-MP was not significantly altered following incubation with PLA2 inhibitor OBAA (p=0.29 
OBAA vs. untreated) but was dramatically reduced following NOS inhibition with L-NAME. A 
dose of 10
-4
 M 3-MP produced an 8.2±4.3% increase in pre-constriction tone with L-NAME 
incubation compared to 68.6±26.2% increase in tone in untreated vessels (p=0.026). Removal of 
the endothelium similarly abolished vasoconstrictive effect of 3-MP and unmasked its 
vasodilatory effect: 10
-4
 M produced a 7.9±6.5% decrease in tone in denuded vessels compared 
to the 68.6±26.2% increase in tone in endothelial-intact vessels (p=0.034). 
NaHS caused dose-dependent vasoconstriction in the coronary arteries (Fig. 3.4B): a 
4.9±3.7% increase in pre-constriction tone occurred with 10
-5
 M, 18.3±4.7% increase occurred 
with 10
-4
 M (p=0.029 vs. 10-5 M), and 218.5±52.0% occurred with 10
-3
 M (p=0.0025 vs. NaHS 
10
-4
 M). Following PLA2 inhibition with OBAA, NaHS also produced dose-dependent 
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vasoconstriction but to a lesser degree: 10
-5
 M produced a 95.9±30.9% increase in pre-
constriction tone with OBAA incubation compared to 218.0±52.0% increase in pre-constriction 
tone in untreated vessels (p=0.039). Following L-NAME incubation, NaHS induced dose-
dependent vasodilation: 10
-5
 M NaHS increased pre-constriction tone by 2.8±0.9% while 10
-4
 M 





NaHS further decreased tone to 76.9±-12.9% of pre-constriction tone (p=0.001 compared to 
NaHS 10
-4
 M). In endothelial-denuded coronary arteries, NaHS also had little vasoconstrictive 
effect at 10
-5
 M and 10
-4




 M NaHS reduced pre-
constriction tone by 76.5±7.9% in denuded vessels compared to 218.5±52.0% increase in tone in 
endothelial-intact vessels (p=0.00081). 
Representative traces of 3-MP dose responses are shown in Fig. 3.5 for untreated (A) and 
with OBAA incubation (B), L-NAME incubation (C), and endothelial denuding (D) and NaHS 
dose response for untreated (E), with OBAA incubation (F), L-NAME incubation (G), and 
endothelial denuding (H). 
 
3.3.5. NO-H2S interaction 
Since enhanced pre-constriction tone could be explained by decreased NO 
bioavailability, we tested whether H2S had a direct effect on NOS activity and NO production. 
Maximum endothelial-mediated vasorelaxation with 10
-5
 M Ach was not different between 
vessels pre-constricted only with U46619 and vessels that exhibited increased pre-constriction 
tension from the addition of 10
-3
 M NaHS or 10
-4
 M 3-MP (Fig. 3.6A).  Ach-induced 
vasorelaxation was 86.0±2.4% for U46619 only pre-constricted vessels compared to 81.0±7.2% 
relaxation for vessels with enhanced pre-constriction tone from NaHS and 72.7±8.6% relaxation 
65 
 
for vessels with increased pre-constriction tone from 3-MP.  Ach-induced vasorelaxation was 
also not significantly reduced with L-NAME incubation compared to untreated vessels: 
vasorelaxation was 65.5±21.4% with L-NAME incubation compared to 86.0±2.4% in untreated 
U46619 only vessels. 
We next tested whether NO could directly interact with H2S.  Fluorescence intensity 
increased with increasing dose of NaHS, demonstrating that AzMC reacted with NaHS (Fig. 
3.6B). Increasing SNP concentration caused decreasing fluorescence intensity and therefore H2S 
availability (Fig. 3.6C). 
 
3.4. DISCUSSION 
We investigated the role of H2S and the contribution of vascular H2S producers CSE and 
MPST in coronary tone vasoregulation. We demonstrate that CSE is not a significant contributor 
to coronary vasoregulation and provide evidence that supports the involvement of MPST in 
coronary vasoregulation. We further describe H2S as a coronary vasoconstrictor when NO 
bioavailability is physiological and vasodilator in the absence of NO. 
Protein abundance measurement by Western blot showed that CSE and MPST are 
expressed in human and rat vascular tissue, although the relative expression between vascular 
beds varies between the two species. CSE expression in HCAECs was slight compared to 
HAECs and MPST expression was similar between the cell lines. In contrast, CSE expression 
was similar between rat coronary and rat aorta while MPST expression was robust in the aorta 
and slight in the coronary artery. The difference in expression could be due to species 
differences. Alternatively, the inconsistency could be due to differences in vascular health. CSE 
and MPST expression have been shown to be influenced by pathological conditions. In a mouse 
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heart failure model, mice with heart failure induced by thoracic aortic constriction had elevated 
CSE expression and reduced MPST expression in the cardiac tissue [70].  While the rats from 
which the tissue was harvested can be considered healthy, we did not ascertain the vascular 
health status of the donors of the human cell lines.  Nevertheless, both sets of protein expression 
data demonstrate that both CSE and MPST are expressed in the coronary artery and support the 
possibility of endogenous H2S production in the coronary vasculature.  
Michaelis-Menten kinetics of CSE and MPST were examined in vitro using rat liver 
homogenate. For 3-MP, the Km value was 0.46±0.14 mM 3-MP.  The CSE reaction did not 
reach Vmax at 50 mM L-cysteine, a concentration far exceeding physiologically relevant L-
cysteine values.  Previously reported Km values is 1.2±0.1 mM 3-MP for wild-type rat liver-
derived MPST [68] and 1.9 mM L-cysteine for wild-type human CSE [71].  Differences in 
reported values can be attributed to reaction conditions.  In the previous studies, both reactions 
were performed at basic pH, pH 9.55 for the MPST reaction and pH 8.2 for the CSE reaction, 
while the reactions in this study were performed at pH 7.0.  The Km value of human CSE for L-
cysteine has also been shown to vary significantly with polymorphic variants [72]. 
In vitro amperometric H2S measurement showed that H2S produced through the MPST 
pathway was significantly greater than through the CSE pathway. Enzymatic activity conditions, 
however, were not equivalent. The MPST reaction was performed at twice the Km value of 
MPST, thereby maximizing MPST activity. The CSE reaction was performed at the highest 
substrate concentration tested in the liver homogenate, 50 mM. While this L-cysteine 
concentration is presumably less than the Km of the enzyme, it is significantly higher than 
concentrations that are physiologically relevant.  Even under supra-physiological substrate 
concentrations, amperometric signal did not increase significantly above baseline, supporting 
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that under physiological conditions, H2S production does not appear to be mediated by CSE.  In 
comparison, a significant increase in amperometric signal from baseline with 3-MP incubation 
supports that MPST is a source of endogenous H2S in the coronary vasculature. 
In vivo coronary vasorelaxation response in CSE-deficient and CSE-inhibited mice were not 
different from untreated wild-type mice. In conjunction with the lack of CSE-mediated H2S 
production in vitro, these in vivo data further support the notion that CSE-derived H2S does not 
significantly contribute to coronary vasoregulation. Our findings are confirmed by previous 
studies that reported lack of coronary vasodilation upon addition of L-cysteine, suggesting 
minimal involvement of CSE in coronary tone modulation [61,64].  The insignificant role of 
CSE-produced H2S in the coronary vasculature seems counterintuitive given the significant role 
of CSE-produced H2S in regulating tone of the resistance arteries [57].  However, endothelial 
protein expression and associated phenotypic traits have been shown to vary by vascular bed. For 
instance, in the heart, endocardial endothelial cells express connexin (CX) 43, CX40, and CX37 
while myocardial capillary endothelial cells do not, consistent with the observation that 
endocardial endothelial cells possess a larger number of gap junctions than myocardial 
endothelial cells [73].  It is therefore not an unreasonable possibility that the coronary arteries, 
which are controlled locally, have different main vasoactive mediators than the resistance 
arteries, which are controlled neurohumorally. 
We demonstrated in vitro that the coronary artery can produce H2S by the MPST 
pathway. Because direct MPST inhibitors are currently unavailable and transgenic deletion 
model was not readily accessible, we determined if MPST was important physiologically using 
ex vivo wire myography.  Vasoactive response to MPST substrate 3-MP was similar to the 
vasoactive response to H2S donor NaHS. The vasoconstrictive effects were not significantly 
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altered with PLA2 inhibition but disappeared with NOS inhibition and endothelial denudation. 
These data support that the effects of 3-MP are mediated through MPST production of H2S as 
opposed to direct vascular effects of 3-MP. Although 3-MP-induced vasoconstriction was 
removed by L-NAME incubation and endothelial removal, 3-MP was not observed to induce 
vasodilation to the same degree as NaHS. Lack of vasodilatory effects of 3-MP could be due to 
insufficient substrate amount to produce the amount of H2S necessary for vasodilation. Coronary 
vasodilation was observed in this study, and has been previously reported, to occur at 1 mM 
NaHS. This concentration of H2S may not have been possible to produce in vivo with the 3-MP 
concentration used. 
Interestingly, we observe vasoconstrictive effects of NaHS in untreated coronary arteries, 
which contradicts previous studies that reported vasodilatory effects of NaHS [61-64].  
However, NaHS dose response conducted simultaneously in aortic rings from the same 
experimental animals (Fig. 3.7) was consistent with published findings of the dual effect of 
NaHS in rat aorta [60,74].  The vasoconstrictive effect of NaHS in the coronary artery described 
in this study is therefore not an artifact of differences in experimental procedure.  We 
demonstrate, however, that the vasoconstrictive effect of NaHS is eNOS and therefore NO 
dependent. NOS inhibition with L-NAME yielded no vasoconstriction and only vasodilation. 
Similar response observed with endothelial denuding identified the involvement of eNOS and 
eNOS-derived NO. 
Reducing NO bioavailability through eNOS inhibition has been shown to further increase 
pre-constriction tension [42].  The enhanced vasoconstriction with addition of NaHS observed in 
this study could therefore occur through eNOS inhibition or NO scavenging. Both H2S 
interference with eNOS activity as well as H2S reaction with NO have been previously 
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described. H2S was shown to cause a dose-dependent decrease in activity of recombinant bovine 
eNOS.  The resulting reduction in NO bioavailability was associated with the observed 
vasoconstrictive effects of NaHS in rat and mouse aorta [60]. Aortic vasoconstriction observed 
at low NaHS doses was attributed to the vasoconstrictive effects of reduced NO bioavailability 
overriding the vasodilatory effects of H2S.  Aortic vasodilation observed at high NaHS doses was 
attributed to the vasodilatory effects of H2S overriding the vasoconstrictive effects of decreased 
NO bioavailability. The reported H2S inhibition of eNOS appears to contradict other studies that 
demonstrated that exogenous H2S promoted eNOS function and eNOS production of NO 
[74,75].  However, the duration of the exogenous H2S administration was different between the 
studies. H2S donor treatment was chronic in the studies showing cooperative effects of H2S on 
eNOS function and acute in the study that showed dose-dependent decrease in eNOS activity as 
well as this study. H2S has also been shown to react with NO to form a nitrosothiol, 
demonstrating the scavenging effect of H2S.  Mixing NaHS with SNP reduced the vasodilatory 
effects of SNP in pre-constricted rat aortic rings, further supporting that H2S reacted with NO 
and reduced NO bioavailability through scavenging [74,76]. 
Our ex vivo vasoreactivity data showed that endothelial-mediated relaxation was maximal 
after NaHS-induced vasoconstriction. NOS inhibition with L-NAME also did not significantly 
attenuate endothelial-mediated relaxation, which would suggest that eNOS activity cannot be 
evaluated by maximum Ach-induced relaxation.  However, we note that the addition of 10
-5
 M 
Ach after L-NAME incubation resulted in complete relaxation in some ring sections and no 
vasorelaxation in other sections from the same animal. This dual effect when averaged resulted 
in overall minimal impairment of Ach-induced vasorelaxation with a large standard error.  10
-5
 
M Ach consistently induced complete relaxation between ring sections and animals for both 
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NaHS and 3-MP, supporting that eNOS activity was truly unimpaired.  This ex vivo 
vasoreactivity data therefore support that H2S-induced vasoconstriction is not through inhibition 
of eNOS activity. 
Our fluorometric data demonstrated the scavenging interaction of H2S and NO. Whether 
the reaction product of H2S and NO is also a vasoconstrictor was not tested in this study. 
However, as noted earlier, this reaction product was shown previously to not have vasoactive 
effects [74,76]. 
Vasoconstriction observed in this study can therefore be attributed directly to decreased 
NO bioavailability. Because only the vasodilatory effects of NaHS were observed in the absence 
of NO, either by L-NAME inhibition or by endothelial denuding, we agree that H2S is a 
vasodilator in the coronary vasculature. We further conclude that its vasoconstrictive effects are 
due to its scavenging interaction with NO. The NO-dependency of the vasoactive effects of H2S 
suggests a change in role from regulatory to vasodilatory with development of coronary artery 
disease. Under healthy conditions with physiological NO bioavailability, H2S appears to 
primarily regulate NO. In disease conditions with diminished NO bioavailability, H2S could 
serve as a compensatory vasomediator. By extension, these findings support that exogenous H2S 
induces vasoconstriction in healthy coronary arteries and vasodilation in diseased coronary 
arteries. Therapies involving administration of exogenous H2S would therefore benefit coronary 
artery disease patients but would be counterproductive as a supplement for patients with healthy 
coronary arteries. 
 A limitation of this is study is the absence of H2S measurement in the bath during the 
wire myograph experiments to confirm that the effects of 3-MP are due to MPST-mediated H2S 
production. This detection was limited by the sensitivity of the amperometric probe in a noisy 
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environment. Nevertheless, similar effects and mechanism of action between 3-MP and NaHS 


























Figure 3.1. CSE and MPST expression in the coronary artery. Protein expression was measured 
in coronary endothelial cells from human (HCAECs) (A) and intact coronary artery from rat (B). 
Human aortic endothelial cells (HAECs) and rat aorta were used as positive controls. CSE 
expression in HCAECs was not as robust as in HAECs. MPST expression was similar between 
the two cell lines. Rat coronary expressed CSE in similar abundance as rat aorta. However, 







Figure 3.2. In vitro amperometric measurement of tissue H2S production. Michaelis-Menten 
kinetics of MPST was characterized in rat liver homogenate by measuring amount of H2S 
produced by increasing concentrations of 3-MP (A). Km of MPST was 0.46±0.14 mM. Kinetic 
behavior of CSE was evaluated by measuring amount of H2S produced by increasing 
concentration of L-cysteine (B). Km and Vmax of CSE was not reached under the conditions 
tested. For coronary H2S production, rat coronary homogenate was incubated in 1mM 3-MP to 
measure MPST-mediated H2S production and in 50mM L-cysteine to measure CSE-mediated 
H2S production (C). Amperometric signal was significantly greater with 3-MP incubation than 





Figure 3.3. In vivo coronary vasorelaxation in CSE knockout and pharmacologically-inhibited 
mice. Coronary vasorelaxation function was evaluated in vivo by measuring increase in flow 
velocity using high-resolution ultrasound. Dose-dependent increase in flow velocity to ATP, 
representing agonst-induced vasorelaxation, and dobutamine, representing metabolic demand-
induced vasorelaxation, were obtained. CSE activity was inhibited by intravenous administration 
of 50 mg/kg propargylglycine (PPG) 30 minutes before flow velocity measurement. ATP-
induced vasorelaxation response was not different between wild-type (WT), PPG-treated wild-
type, and CSE knockout mice (A). Vasorelaxation response to dobutamine-induced increase in 





Figure 3.4. Vasoactive effects of 3-MP and NaHS. Physiological role of MPST in coronary 
vasoregulation was determined by wire myography in the rat left coronary artery.  Data is 
displayed as percent change from pre-constriction tone. 3-MP induced vasoconstriction in pre-
constricted arteries in a dose-dependent manner (A). Incubation with 10 µM phospholipase 2A 
inhibitor OBAA did not alter 3-MP vasoconstrictive effects. 100 µM L-NAME incubation 
significantly reduced 3-MP-mediated vasoconstriction. Endothelial removal resulted in 3-MP 
mediated vasodilation. Exogenous H2S donor NaHS also induced vasoconstriction in pre-
constricted arteries in a dose-dependent manner (B). OBAA incubation attenuated NaHS-
induced vasoconstriction. L-NAME and endothelial denuding removed NaHS-induced 
vasoconstriction and only presented NaHS-induced vasodilation.   # p<0.05 and ##p<0.01 
comparing between previous dose within the same treatment group; *p<0.05 and **p<0.01 when 





Figure 3.5. 3-MP and NaHS dose response traces. Representative vasotension traces of 3-MP 
dose response in untreated coronary artery (A) and after incubation with 10 µM OBAA (B) and 
100 µM L-NAME (C) and endothelial denudation (D). NaHS dose response in untreated 











Figure 3.6. H2S-mediated vasoconstriction via reduced eNOS activity and decreased NO 
bioavailability. eNOS activity was measured by percent relaxation with addition of 10
-5
 M 
acetylcholine (Ach) bolus after maximum increase in pre-constriction tension induced by NaHS, 
3-MP, or L-NAME (A). Ach relaxation response was compared to vessels pre-constricted with 
U46619 only.  Maximum Ach-induced endothelial-mediated relaxation was not different 
between U46619 only and NaHS, 3-MP, and L-NAME-constricted vessels. H2S effect on NO 
bioavailability was measured in vitro by fluorometric probe 7-azido methylcoumarin (AzMC). 
Fluorescence intensity of AzCM increased with H2S dose (B). Addition of increasing dose of NO 
donor sodium nitroprusside (SNP) to 10
-3
 M NaHS resulted in a dose-dependent decrease in 














Figure 3.7. Vasoactive effects of NaHS in rat aorta. Representative trace of NaHS dose response 
(A). NaHS causes vasoconstriction at lower doses and vasodilation at higher doses (B), 














SUMMARY & FUTURE DIRECTIONS    
Chapter 2 examined whether ionizing radiation exposure initiated the same mechanistic 
events that promote the development of coronary artery disease, namely increased superoxide 
production occurring with impaired coronary endothelial function.  Rats exposed to ionizing 
radiation exhibited reduced coronary flow in vivo.  Decreased coronary flow was associated with 
both decreased aortic diastolic pressure and elevated superoxide content in the coronary artery.  
Diminished diastolic pressure was attributed to decreased heart rate. Reduction of superoxide 
production by xanthine oxidase inhibition partially restored basal coronary flow and coronary 
superoxide content.  However, in vivo vasodilatory response was not improved. Moreover, 
endothelial function was preserved in irradiated rats. These findings support that radiation-
associated coronary artery disease is initiated by increased superoxide level, which leads to 
reduced NO bioavailability and diminished coronary vasodilatory response in vivo.  The data 
further suggest that excess superoxide production precedes coronary endothelial dysfunction 
characteristic of coronary artery disease. 
These findings support that targeting excess ROS production can potentially prevent 
future development of coronary artery disease. Pre-emptive activation of the nuclear factor-like 2 
(Nrf2)-controlled antioxidant response pathway is a promising intervention method.  Several 
studies have demonstrated the benefits of Nrf2 activation in protecting cells from oxidative 
damage. Radioresistance of cancer cells was attributed to constitutively active Nrf2 pathway 
[77] while compounds that enhanced cell survival after radiation exposure were shown to work 
through Nrf2 [78,79].  Moreover, a number of food sources can activate Nrf2, including 
sulforaphane found in broccoli sprouts and resveratrol found in red wine. Nrf2-based 
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interventions are therefore potentially easy to implement for defense against occupation-
associated ionizing radiation exposure. 
Chapter 3 investigated the role of endogenously produced H2S in regulating coronary 
tone. Both vascular H2S producing enzymes cystathionine gamma lyase (CSE) and 
mercaptopyruvate sulfertransferase (MPST) proteins were detected in human coronary 
endothelial cells and rat coronary arteries. In vitro measurement of H2S production showed that 
the rat coronary artery can produce H2S through the MPST pathway but not through the CSE 
pathway.  Both pharmacologic inhibition and genetic deletion of CSE did not alter coronary 
vasodilatory function in vivo, supporting that CSE-produced H2S does not have a significant role 
in coronary vasoregulation. Ex vivo coronary vasoreactivity response to MPST substrate 3-
mercaptopyruvate (3-MP) was similar to the vasoreactivity response to H2S donor sodium 
hydrosulfide (NaHS), supporting that vasoactive effects of 3-MP were through MPST-mediated 
production of H2S.  The data demonstrate that H2S production in the coronary artery is mediated 
by MPST and not CSE, contrary to other vascular beds where CSE has a significant role.  The 
data further show that the vasoactive effect of H2S is NO dependent: H2S induces coronary 
vasoconstriction in the presence of NO and vasorelaxation in the absence of NO. 
Vasoconstrictive effects of H2S appear to be due to its scavenging of NO and the resulting 
decrease in NO bioavailability. 
 These findings are particularly intriguing when considering the potential 
contraindications of H2S-based treatments for heart disease. H2S is associated with promoting 
cardiovascular health.  Besides gaseous H2S, H2S can be supplied from dietary sources, notably 
garlic.  In fact, the cardiovascular benefits of garlic were shown to be a result of its H2S donor 
properties [80].  Dietary H2S supplementation therefore could promote coronary vasodilation 
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and cardiac health in coronary artery disease patients. In healthy patients, however, or patients 
with less severe coronary artery disease, exogenous supplementation may have adverse effects 
because the vasoconstrictive properties of H2S would be more relevant.  
Another interesting application is sulfhydryl-containing angiotensin converting enzyme 
(ACE) inhibitors.  Sulfhydryl-ACE inhibitor zofenopril has been reported to have additional 
beneficial effects compared to dicarobxylate-ACE inhibitors, including improved clinical 
outcomes in patients with acute myocardial infarction and congestive failure as well as improved 
flow-mediated vasodilation.  The beneficial effects of zofenopril recently were shown to be due 
to its H2S donor properties [81].  As ACE inhibitors are administered to heart disease patients 
who would most likely have diminished NO bioavailability, the vasoconstrictive effects of H2S 
released by zofenopril may not be problematic.  However, for patients with less severe 
symptoms, the vasoconstrictive effects may manifest.  Further examination of the vasoactive 
influences of exogenous H2S donors on the coronary artery would clarify potential adverse 












CONCLUDING REMARKS  
This dissertation demonstrates the use of novel ultrasound-based methods to evaluate 
coronary and vascular function.  Moreover, this dissertation illustrates how altering the 
bioavailability of NO influences coronary vasodilatory function as well as the roles of other 
vasoactive mediators in coronary vasoregulation.  Chapter 2 demonstrated how reduced coronary 
vasoreactivity in vivo did not arise from impaired endothelial or smooth muscle function, but 
excess scavenging of NO by elevated coronary ROS content.  Chapter 3 showed how the role of 
MPST-produced H2S changed with NO bioavailability: H2S induced vasoconstriction in the 
presence of NO and vasodilation in the absence of NO.   
These studies could suggest H2S as a vanguard compensatory molecule in the absence of 
NO.  However, in a situation of decreased NO bioavailability, H2S may still act as a regulatory 
molecule.  This role would explain why after ionizing radiation exposure, where the increased 
ROS presumably decreases NO bioavailability, basal coronary flow is not preserved.  H2S also 
may not be a potent compensatory mechanism as the vasodilatory effects of H2S are observed 
only at higher concentrations.  Moreover, most pathological vascular conditions are associated 
with reduced NO bioavailability and not complete absence of NO.  Nevertheless, these studies 
reinforce the importance of NO in regulating coronary tone.  
This dissertation also demonstrates how changes in in vivo response may not be reflected 
in the ex vivo measurement. In Chapter 2, attenuated vasodilatory response observed in vivo did 
not correspond to impaired ex vivo vasodilatory response.  In Chapter 3, increased aortic stiffness 
observed in vivo was not associated with increased stiffness measured ex vivo.  These findings 
show the significance of in vivo influences on vascular function and further illustrate the power 
of implementing a multi-level approach in studying vascular function.  Changes in cellular 
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signaling can be correlated to changes in physiological function, providing a more complete 
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